{"PMC7163610": [["Reliability of URT endoscopic grading", [["URT endoscopic grading", "TEST", 15, 37]]]], "20d2fee18b63c9f63d9fe0e5b6685ad2ae186db8": [["A fundamental understanding of how bacteria and viruses become airborne remains elusive yet is central to understanding their role in atmospheric processes and the spread of disease.", [["how bacteria", "PROBLEM", 31, 43], ["viruses", "PROBLEM", 48, 55], ["disease", "PROBLEM", 174, 181], ["spread", "OBSERVATION_MODIFIER", 164, 170]]], ["Microbial transmission and survival are influenced by particle size, relative humidity, temperature, environmental composition, and virus type [1] [2] [3] , yet the mechanisms controlling their initial airborne transmission are poorly understood.", [["size", "OBSERVATION_MODIFIER", 63, 67]]], ["The atmosphere contains vast bacterial (6 \u00d7 10 4 -1.6 \u00d7 10 7 cells m \u22123 ) and viral populations arising from a wide range of aquatic, terrestrial, and organismal biomes [4] [5] [6] [7] .", [["cells", "ANATOMY", 61, 66], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 169, 184], ["The atmosphere", "TEST", 0, 14], ["vast bacterial", "TEST", 24, 38], ["cells m", "TEST", 61, 68], ["viral populations", "PROBLEM", 78, 95], ["vast", "OBSERVATION_MODIFIER", 24, 28], ["bacterial", "OBSERVATION_MODIFIER", 29, 38], ["viral populations", "OBSERVATION", 78, 95], ["wide", "OBSERVATION_MODIFIER", 111, 115]]], ["As the ocean covers 71% of the planet and contains 60-90% of the world's prokaryotes by cell abundance in open ocean and sediment 8 , sea spray aerosol (SSA) represents a significant yet largely understudied source of airborne bacteria and viruses.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["cell abundance", "PROBLEM", 88, 102], ["open ocean", "TREATMENT", 106, 116], ["sediment", "TREATMENT", 121, 129], ["sea spray aerosol", "TREATMENT", 134, 151], ["airborne bacteria", "PROBLEM", 218, 235], ["viruses", "PROBLEM", 240, 247], ["airborne bacteria", "OBSERVATION", 218, 235]]], ["Bacteria in aerosols can travel as far as 11,000 km, with air residence times of days to weeks 1, 5, 9 , and algal viruses maintain infectivity over several hundred kilometers 10 .", [["1, 5, 9", "CHEMICAL", 95, 102], ["algal viruses", "ORGANISM", 109, 122], ["Bacteria", "PROBLEM", 0, 8], ["algal viruses", "PROBLEM", 109, 122], ["aerosols", "OBSERVATION", 12, 20], ["infectivity", "OBSERVATION_MODIFIER", 132, 143]]], ["Airborne bacteria and viruses influence climate by serving as cloud seeds and inducing ice nucleation [11] [12] [13] [14] .", [["Airborne bacteria", "PROBLEM", 0, 17], ["viruses", "PROBLEM", 22, 29], ["inducing ice nucleation", "TEST", 78, 101], ["viruses", "OBSERVATION", 22, 29]]], ["Microbes detected in clouds and precipitation have major impacts on ice formation and precipitation efficiency, yet their source remains largely unknown 15 .", [["ice", "SIMPLE_CHEMICAL", 68, 71], ["Microbes", "PROBLEM", 0, 8], ["ice formation", "TREATMENT", 68, 81], ["precipitation efficiency", "PROBLEM", 86, 110], ["precipitation efficiency", "OBSERVATION_MODIFIER", 86, 110]]], ["Airborne microbes also impact air quality through transmission of allergens and pathogens 16 .", [["Airborne microbes", "PROBLEM", 0, 17], ["allergens", "PROBLEM", 66, 75], ["pathogens", "PROBLEM", 80, 89], ["air quality", "OBSERVATION", 30, 41]]], ["However, identification of species-level contributions of ocean microbes to atmospheric processes and air quality has never been definitely determined.", [["species", "PROBLEM", 27, 34], ["ocean microbes to atmospheric processes", "PROBLEM", 58, 97], ["species", "OBSERVATION_MODIFIER", 27, 34], ["ocean microbes", "OBSERVATION", 58, 72], ["atmospheric processes", "OBSERVATION", 76, 97], ["air quality", "OBSERVATION", 102, 113]]]], "PMC7370869": [["The position statement presented here incorporates the response to the feedback received, while maintaining the key themes that received such resounding endorsement from a very clear majority of the members who responded.Consultation process and feedbackWe summarise the most common suggestions for improvements: All up about a dozen respondents commented that the draft statement appeared somewhat dismissive of the positive changes that may come out of the COVID-19 pandemic or of innovative teaching methods more generally; or that the expectation to return to best practice implied a too rigid adherence to the pre-pandemic status quo; or that the statement lacked an expression of recognition for the academics\u2019 and teachers\u2019 efforts in transitioning online at short notice.", [["the positive changes", "PROBLEM", 413, 433], ["innovative teaching methods", "TREATMENT", 483, 510], ["positive", "OBSERVATION", 417, 425]]], ["All members are invited to contribute further and in detail to this debate, through letters to the editors of the Australian Physics, see below.Continuing the conversationThe key purpose of releasing this statement is for it to act as a catalyst for a broad and open debate on this important topic.Continuing the conversationThe physics community, and hence the AIP, needs to be central to this discussion.", [["AIP", "DISEASE", 362, 365], ["a catalyst", "TREATMENT", 235, 245], ["a broad and open debate", "PROBLEM", 250, 273]]], ["Because of this experience, we should assert our voice\u2014or rather our multiple voices\u2014in this debate, loud and clear.Continuing the conversationThe prepared statement reflects the view of the AIP National Executive and the Chair of the Accreditation Committee that physics degrees and education are, as they stand, generally of high quality and fit-for-purpose.", [["AIP", "DISEASE", 191, 194], ["clear", "OBSERVATION", 110, 115]]], ["But we also need to identify and articulate clearly the positive elements of our current (pre-COVID) practices\u2014those pillars that ensure its ongoing success\u2014and ensure that these are preserved in times of change and times of tight budgets.Continuing the conversationOne theme that has been given a stronger voice during the discussion of the \u201cCOVID-19\u201d position statement for physics education was with us already as a quiet murmur.", [["our current (pre-COVID) practices", "TREATMENT", 77, 110], ["those pillars", "TREATMENT", 111, 124], ["the \u201cCOVID", "TREATMENT", 338, 348], ["physics education", "TREATMENT", 376, 393], ["a quiet murmur", "PROBLEM", 417, 431], ["preserved", "OBSERVATION", 183, 192]]], ["We would also like to hear your suggestions as to what further steps the AIP could take to protect or enhance the high quality of Australia\u2019s physics degrees throughout and beyond the COVID-19 pandemic and how to promote the appreciation of this beyond our community.Continuing the conversationFeedback for publication is encouraged in the form of letters to the editors of Australian Physics (aip_editor@aip.org.au).", [["AIP", "DISEASE", 73, 76]]]], "PMC7112791": [["IntroductionThe measurement of seroneutralizing antibodies has been used commonly for many years to assess the level of immunity to rabies (Aubert, 1992, Cliquet et al., 1998) and a virus-neutralizing antibody titer of 0.5 IU/ml in sera is the threshold of seroconversion to rabies vaccination as recommended by the World Health Organization (WHO).", [["sera", "ANATOMY", 232, 236], ["rabies", "DISEASE", 132, 138], ["rabies", "DISEASE", 275, 281], ["rabies", "ORGANISM", 132, 138], ["sera", "ORGANISM_SUBSTANCE", 232, 236], ["rabies", "ORGANISM", 275, 281], ["seroneutralizing antibodies", "PROTEIN", 31, 58], ["rabies", "SPECIES", 132, 138], ["rabies", "SPECIES", 275, 281], ["seroneutralizing antibodies", "TREATMENT", 31, 58], ["a virus", "TEST", 180, 187], ["neutralizing antibody titer", "TEST", 188, 215], ["seroconversion", "TREATMENT", 257, 271], ["rabies vaccination", "TREATMENT", 275, 293]]], ["Detection and quantitation of antibodies against rabies virus (RABV) are also of prime importance for assessing the efficacy of rabies vaccination campaigns.", [["antibodies against", "GENE_OR_GENE_PRODUCT", 30, 48], ["rabies virus", "ORGANISM", 49, 61], ["RABV", "ORGANISM", 63, 67], ["rabies", "ORGANISM", 128, 134], ["antibodies", "PROTEIN", 30, 40], ["rabies virus", "SPECIES", 49, 61], ["rabies virus", "SPECIES", 49, 61], ["RABV", "SPECIES", 63, 67], ["rabies", "SPECIES", 128, 134], ["Detection", "TEST", 0, 9], ["antibodies", "PROBLEM", 30, 40], ["rabies virus", "PROBLEM", 49, 61], ["rabies vaccination campaigns", "TREATMENT", 128, 156]]], ["The rapid fluorescent focus inhibition test (RFFIT) (Smith et al., 1973) and the fluorescent antibody virus neutralization (FAVN) test (Cliquet et al., 1998) are the only in vitro methods recommended by the World Organization for Animal Health (OIE) for measuring virus neutralizing antibodies.", [["virus neutralizing antibodies", "PROTEIN", 264, 293], ["The rapid fluorescent focus inhibition test", "TEST", 0, 43], ["the fluorescent antibody virus neutralization", "TEST", 77, 122], ["measuring virus neutralizing antibodies", "PROBLEM", 254, 293]]], ["In addition, the procedures are time-consuming, and only a limited number of samples can be processed at one time.", [["samples", "ANATOMY", 77, 84], ["samples", "CANCER", 77, 84]]], ["They are therefore inefficient and expensive for human and animal clinics in developing countries without trained personnel.", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54]]], ["The challenges in the 21st century for diagnostic test developers are two-fold: first, to achieve internationally accepted validation of a test; and second, to overcome financial and logistical barriers that prevent implementation of a test in the developing countries with the greatest need (Fooks et al., 2009).", [["diagnostic test", "TEST", 39, 54], ["a test", "TEST", 137, 143], ["logistical barriers", "TREATMENT", 183, 202], ["a test", "TEST", 234, 240]]], ["A more convenient and affordable diagnostic test for antibodies against rabies virus should be developed in countries where rabies is endemic and where resources are limited.IntroductionThe immunochromatographic assay, also referred to as lateral flow device or simply a strip assay, is a technique in which a cellulose membrane is used as the carrier and a colloidal gold-labeled antigen or antibody is used as the tracer (Zhang et al., 2006, Zhang et al., 2009a, Zhang et al., 2009b).", [["membrane", "ANATOMY", 320, 328], ["rabies virus", "DISEASE", 72, 84], ["rabies", "DISEASE", 124, 130], ["rabies virus", "ORGANISM", 72, 84], ["rabies", "ORGANISM", 124, 130], ["membrane", "CELLULAR_COMPONENT", 320, 328], ["antibodies", "PROTEIN", 53, 63], ["colloidal gold-labeled antigen", "PROTEIN", 358, 388], ["rabies virus", "SPECIES", 72, 84], ["rabies", "SPECIES", 124, 130], ["affordable diagnostic test", "TEST", 22, 48], ["antibodies", "TREATMENT", 53, 63], ["rabies virus", "PROBLEM", 72, 84], ["The immunochromatographic assay", "TEST", 186, 217], ["lateral flow device", "TEST", 239, 258], ["a strip assay", "TEST", 269, 282], ["a technique", "TEST", 287, 298], ["a cellulose membrane", "TREATMENT", 308, 328], ["a colloidal gold-labeled antigen", "TREATMENT", 356, 388]]], ["Although this method has only been used for qualitative analysis so far, it provides rapid detection of antigens and antibodies, and thus possesses advantages over the conventional immunoassays, such as low cost, inexpensive equipment, simplicity of procedure, rapid operation, and long-term stability over a wide range of environmental conditions.", [["antigens", "PROTEIN", 104, 112], ["antibodies", "PROTEIN", 117, 127], ["qualitative analysis", "TEST", 44, 64], ["antibodies", "PROBLEM", 117, 127], ["the conventional immunoassays", "TEST", 164, 193], ["inexpensive equipment", "TREATMENT", 213, 234], ["procedure", "TREATMENT", 250, 259], ["rapid operation", "TREATMENT", 261, 276], ["long-term stability", "PROBLEM", 282, 301], ["long-term stability", "OBSERVATION_MODIFIER", 282, 301]]], ["These characteristics render a test ideally suited for on-site testing by untrained personnel (Peng et al., 2007).", [["a test", "TEST", 29, 35]]], ["Immunogold labeling has been applied widely for diagnosis of infection and for antibody detection (Cui et al., 2008, Hedstrom et al., 1998, Mikawa et al., 2009, Oku et al., 2001, Smits et al., 2001, Yang et al., 2010).", [["infection", "DISEASE", 61, 70], ["Immunogold labeling", "TREATMENT", 0, 19], ["infection", "PROBLEM", 61, 70], ["antibody detection", "TEST", 79, 97], ["infection", "OBSERVATION", 61, 70]]], ["A rapid immunochromatographic test kit for rabies virus detection was developed and evaluated using clinical samples.", [["rabies virus", "ORGANISM", 43, 55], ["rabies virus", "SPECIES", 43, 55], ["A rapid immunochromatographic test kit", "TEST", 0, 38], ["rabies virus detection", "TEST", 43, 65], ["clinical samples", "TEST", 100, 116]]], ["The kit provides a simple and rapid method for detection of infection with rabies (Kang et al., 2007, Nishizono et al., 2008).", [["infection", "DISEASE", 60, 69], ["rabies", "DISEASE", 75, 81], ["rabies", "ORGANISM", 75, 81], ["rabies", "SPECIES", 75, 81], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["In the present study, a rapid, one-step immunochromatographic test strip capable of detecting specifically rabies virus antibodies in serum was developed.Cells and virus ::: Materials and methodsMouse neuroblastoma (MNA) cells were maintained in RPMI 1640 (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY).", [["serum", "ANATOMY", 134, 139], ["Cells", "ANATOMY", 154, 159], ["neuroblastoma (MNA) cells", "ANATOMY", 201, 226], ["fetal bovine serum", "ANATOMY", 303, 321], ["FBS", "ANATOMY", 323, 326], ["Mouse neuroblastoma", "DISEASE", 195, 214], ["rabies", "ORGANISM", 107, 113], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["Cells", "CELL", 154, 159], ["Mouse", "ORGANISM", 195, 200], ["neuroblastoma (MNA) cells", "CELL", 201, 226], ["Mediatech", "ORGANISM_SUBSTANCE", 257, 266], ["bovine", "ORGANISM", 309, 315], ["serum", "ORGANISM_SUBSTANCE", 316, 321], ["FBS", "ORGANISM_SUBSTANCE", 323, 326], ["rabies virus antibodies", "PROTEIN", 107, 130], ["Mouse neuroblastoma (MNA) cells", "CELL_LINE", 195, 226], ["rabies virus", "SPECIES", 107, 119], ["Mouse", "SPECIES", 195, 200], ["bovine", "SPECIES", 309, 315], ["rabies virus", "SPECIES", 107, 119], ["bovine", "SPECIES", 309, 315], ["one-step immunochromatographic test strip", "TEST", 31, 72], ["rabies virus antibodies in serum", "PROBLEM", 107, 139], ["Materials", "TREATMENT", 174, 183], ["methodsMouse neuroblastoma (MNA) cells", "PROBLEM", 188, 226], ["RPMI", "TEST", 246, 250], ["10% fetal bovine serum (FBS", "TREATMENT", 299, 326], ["Mouse neuroblastoma", "OBSERVATION", 195, 214]]], ["The Challenge Virus Standard strain (CVS-11) of RABV was propagated in MNA cells.Reagents ::: Materials and methodsChloroauric acid was purchased from Sigma Company (St. Louis, MO, USA).", [["MNA cells", "ANATOMY", 71, 80], ["Chloroauric acid", "CHEMICAL", 115, 131], ["Chloroauric acid", "CHEMICAL", 115, 131], ["RABV", "ORGANISM", 48, 52], ["MNA cells", "CELL", 71, 80], ["Chloroauric acid", "SIMPLE_CHEMICAL", 115, 131], ["MNA cells", "CELL_LINE", 71, 80], ["RABV", "SPECIES", 48, 52], ["The Challenge Virus", "TREATMENT", 0, 19], ["CVS", "TEST", 37, 40], ["RABV", "PROBLEM", 48, 52], ["methodsChloroauric acid", "TREATMENT", 108, 131], ["MNA cells", "OBSERVATION", 71, 80]]], ["Nitrocellulose membranes, fiberglass, and filter paper were purchased from Millipore Corporation (Billerica, MA, USA).Sera and antisera ::: Materials and methodsFluorescein isothiocyanate (FITC)-conjugated antibody against the rabies viral N protein was purchased from Fujirebio (Melvin, PA).", [["membranes", "ANATOMY", 15, 24], ["Nitrocellulose", "CHEMICAL", 0, 14], ["Fluorescein isothiocyanate", "CHEMICAL", 161, 187], ["Nitrocellulose", "CHEMICAL", 0, 14], ["Fluorescein isothiocyanate", "CHEMICAL", 161, 187], ["FITC", "CHEMICAL", 189, 193], ["Nitrocellulose", "SIMPLE_CHEMICAL", 0, 14], ["Sera", "ORGANISM_SUBSTANCE", 118, 122], ["Fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 161, 187], ["FITC", "SIMPLE_CHEMICAL", 189, 193], ["rabies", "ORGANISM", 227, 233], ["Fluorescein isothiocyanate (FITC)-conjugated antibody", "PROTEIN", 161, 214], ["rabies viral N protein", "PROTEIN", 227, 249], ["rabies", "SPECIES", 227, 233], ["Nitrocellulose membranes", "TREATMENT", 0, 24], ["fiberglass, and filter paper", "TREATMENT", 26, 54], ["Materials", "TEST", 140, 149], ["methodsFluorescein isothiocyanate (FITC)", "TEST", 154, 194], ["conjugated antibody", "TREATMENT", 195, 214], ["the rabies viral N protein", "TEST", 223, 249], ["fiberglass", "OBSERVATION_MODIFIER", 26, 36]]], ["A mouse monoclonal antibody (MAbG63; IgG2a) recognizing epitopes at antigenic site II on the RABV G protein was selected by the Military Institute of Veterinary Science (Changchun).", [["mouse", "ORGANISM", 2, 7], ["IgG2a", "GENE_OR_GENE_PRODUCT", 37, 42], ["RABV G protein", "GENE_OR_GENE_PRODUCT", 93, 107], ["mouse monoclonal antibody", "PROTEIN", 2, 27], ["MAbG63", "PROTEIN", 29, 35], ["IgG2a", "PROTEIN", 37, 42], ["epitopes", "PROTEIN", 56, 64], ["antigenic site II", "PROTEIN", 68, 85], ["RABV G protein", "PROTEIN", 93, 107], ["mouse", "SPECIES", 2, 7], ["mouse", "SPECIES", 2, 7], ["RABV", "SPECIES", 93, 97], ["A mouse monoclonal antibody", "TEST", 0, 27], ["MAb", "TEST", 29, 32], ["IgG2a", "TEST", 37, 42], ["recognizing epitopes at antigenic site", "PROBLEM", 44, 82], ["monoclonal antibody", "OBSERVATION", 8, 27]]], ["The neutralizing potency of the antibody was 18.6 IU/ml at 1 mg/ml for CVS-11 rabies virus detected by the FAVN test.", [["CVS-11 rabies virus", "ORGANISM", 71, 90], ["rabies virus", "SPECIES", 78, 90], ["CVS-11 rabies virus", "SPECIES", 71, 90], ["the antibody", "TEST", 28, 40], ["CVS", "TEST", 71, 74], ["rabies virus", "PROBLEM", 78, 90], ["the FAVN test", "TEST", 103, 116], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16], ["potency", "OBSERVATION_MODIFIER", 17, 24]]], ["Antisera for canine distemper virus (CDV), canine parvovirus (CPV), canine adenovirus (CAV-I), canine parainfluenza virus (CPIV), canine coronavirus (CCV) and rabies virus were prepared in the Military Institute of Veterinary Science (Changchun).", [["canine parvovirus", "DISEASE", 43, 60], ["canine parainfluenza virus", "DISEASE", 95, 121], ["canine coronavirus (CCV) and rabies virus", "DISEASE", 130, 171], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["canine distemper virus", "ORGANISM", 13, 35], ["CDV", "ORGANISM", 37, 40], ["canine parvovirus", "ORGANISM", 43, 60], ["CPV", "ORGANISM", 62, 65], ["canine adenovirus", "ORGANISM", 68, 85], ["CAV-I", "ORGANISM", 87, 92], ["canine parainfluenza virus", "ORGANISM", 95, 121], ["CPIV", "ORGANISM", 123, 127], ["canine coronavirus", "ORGANISM", 130, 148], ["CCV", "ORGANISM", 150, 153], ["rabies virus", "ORGANISM", 159, 171], ["canine distemper virus", "SPECIES", 13, 35], ["canine parvovirus", "SPECIES", 43, 60], ["canine", "SPECIES", 68, 74], ["canine parainfluenza virus", "SPECIES", 95, 121], ["canine coronavirus", "SPECIES", 130, 148], ["rabies virus", "SPECIES", 159, 171], ["canine distemper virus", "SPECIES", 13, 35], ["CDV", "SPECIES", 37, 40], ["canine parvovirus", "SPECIES", 43, 60], ["CPV", "SPECIES", 62, 65], ["canine adenovirus (CAV-I", "SPECIES", 68, 92], ["canine parainfluenza virus", "SPECIES", 95, 121], ["CPIV", "SPECIES", 123, 127], ["canine coronavirus", "SPECIES", 130, 148], ["CCV", "SPECIES", 150, 153], ["rabies virus", "SPECIES", 159, 171], ["Antisera", "TREATMENT", 0, 8], ["canine distemper virus", "PROBLEM", 13, 35], ["canine parvovirus (CPV", "PROBLEM", 43, 65], ["canine adenovirus", "PROBLEM", 68, 85], ["canine parainfluenza virus", "PROBLEM", 95, 121], ["canine coronavirus", "PROBLEM", 130, 148], ["rabies virus", "PROBLEM", 159, 171], ["parainfluenza virus", "OBSERVATION", 102, 121]]], ["Sera from dogs, cats, rabbits and mice that had never been vaccinated were used as negative controls.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["dogs", "ORGANISM", 10, 14], ["cats", "ORGANISM", 16, 20], ["rabbits", "ORGANISM", 22, 29], ["mice", "ORGANISM", 34, 38], ["dogs", "SPECIES", 10, 14], ["cats", "SPECIES", 16, 20], ["rabbits", "SPECIES", 22, 29], ["mice", "SPECIES", 34, 38], ["rabbits", "SPECIES", 22, 29], ["mice", "SPECIES", 34, 38]]], ["A total of 756 clinic sera collected at random from 10 different provinces were evaluated.", [["sera", "ANATOMY", 22, 26], ["sera", "ORGANISM_SUBSTANCE", 22, 26], ["clinic sera", "TEST", 15, 26]]], ["All serum samples were stored at \u201320 \u00b0C until used.Isolation of rabies virus glycoprotein ::: Materials and methodsThe rabies virus glycoprotein (RABV G) was prepared by a modification of a technique which was described previously (Barton and Campbell, 1988, Cox et al., 1977, Smith et al., 2006).", [["serum samples", "ANATOMY", 4, 17], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["rabies virus", "ORGANISM", 64, 76], ["rabies virus glycoprotein", "ORGANISM", 119, 144], ["RABV", "ORGANISM", 146, 150], ["rabies virus glycoprotein", "PROTEIN", 64, 89], ["rabies virus glycoprotein", "PROTEIN", 119, 144], ["RABV G", "PROTEIN", 146, 152], ["rabies virus", "SPECIES", 64, 76], ["rabies virus", "SPECIES", 119, 131], ["rabies virus", "SPECIES", 64, 76], ["rabies virus", "SPECIES", 119, 131], ["RABV", "SPECIES", 146, 150], ["All serum samples", "TEST", 0, 17], ["The rabies virus glycoprotein (RABV G", "TREATMENT", 115, 152], ["a technique", "TREATMENT", 188, 199]]], ["MNA cells were infected with CVS-11 at a multiplicity of infection (MOI) of 0.1, and incubated at 32 \u00b0C for 4 d.", [["MNA cells", "ANATOMY", 0, 9], ["CVS-11", "CHEMICAL", 29, 35], ["multiplicity of infection", "DISEASE", 41, 66], ["MNA cells", "CELL", 0, 9], ["MNA cells", "CELL_LINE", 0, 9], ["MNA cells", "PROBLEM", 0, 9], ["CVS", "TEST", 29, 32], ["infection", "PROBLEM", 57, 66], ["infection", "OBSERVATION", 57, 66]]], ["Culture fluid was collected, cells were removed by centrifugation (1500 \u00d7g, 20 min, 4 \u00b0C), and the virus was pelleted by ultracentrifugation at 45,000 \u00d7g for 2 h at 4 \u00b0C. Pellets were resuspended in PBS and left overnight at 4 \u00b0C. Beta-propiolactone (BPL, Sigma, Inc.) was added to the virus solution to a final BPL dilution of 1:3000.", [["Culture fluid", "ANATOMY", 0, 13], ["cells", "ANATOMY", 29, 34], ["Pellets", "ANATOMY", 171, 178], ["Beta-propiolactone", "CHEMICAL", 231, 249], ["BPL", "CHEMICAL", 251, 254], ["Beta-propiolactone", "CHEMICAL", 231, 249], ["BPL", "CHEMICAL", 251, 254], ["cells", "CELL", 29, 34], ["Beta-propiolactone", "SIMPLE_CHEMICAL", 231, 249], ["BPL", "SIMPLE_CHEMICAL", 251, 254], ["Sigma", "SIMPLE_CHEMICAL", 256, 261], ["Culture fluid", "TEST", 0, 13], ["the virus", "TREATMENT", 95, 104], ["Pellets", "TREATMENT", 171, 178], ["Beta-propiolactone (BPL, Sigma, Inc.)", "TREATMENT", 231, 268], ["the virus solution", "TREATMENT", 282, 300], ["fluid", "OBSERVATION", 8, 13], ["left", "ANATOMY_MODIFIER", 207, 211]]], ["Incubation continued overnight at 4 \u00b0C, followed by 2 h at 37 \u00b0C to permit complete hydrolysis of the remaining BPL.", [["BPL", "SIMPLE_CHEMICAL", 112, 115], ["Incubation", "TREATMENT", 0, 10], ["BPL", "OBSERVATION", 112, 115]]], ["Inactivated virus was then layered over a sucrose gradient and pelleted by ultracentrifugation (61,000 \u00d7g, 90 min, 4 \u00b0C).", [["sucrose", "CHEMICAL", 42, 49], ["sucrose", "CHEMICAL", 42, 49], ["sucrose", "SIMPLE_CHEMICAL", 42, 49], ["Inactivated virus", "PROBLEM", 0, 17], ["a sucrose gradient", "TREATMENT", 40, 58]]], ["The pelleted virus was resuspended in Tris-buffered saline containing EDTA (0.13 M NaCl/0.05 M Tris, pH 7.2/0.001 M EDTA).", [["EDTA", "CHEMICAL", 70, 74], ["NaCl", "CHEMICAL", 83, 87], ["Tris", "CHEMICAL", 38, 42], ["EDTA", "CHEMICAL", 70, 74], ["NaCl", "CHEMICAL", 83, 87], ["Tris", "CHEMICAL", 95, 99], ["EDTA", "CHEMICAL", 116, 120], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 38, 58], ["EDTA", "SIMPLE_CHEMICAL", 70, 74], ["The pelleted virus", "TREATMENT", 0, 18], ["buffered saline containing EDTA", "TREATMENT", 43, 74], ["Tris", "TEST", 95, 99], ["pH", "TEST", 101, 103], ["virus", "OBSERVATION", 13, 18]]], ["The glycoprotein was dissociated from the virus by incubation (1 h, 24 \u00b0C) with 1% Triton X-100 in Tris-buffered saline.", [["Triton X-100", "CHEMICAL", 83, 95], ["Tris", "CHEMICAL", 99, 103], ["Triton X-100", "SIMPLE_CHEMICAL", 83, 95], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 99, 119], ["glycoprotein", "PROTEIN", 4, 16], ["The glycoprotein", "TREATMENT", 0, 16], ["1% Triton", "TREATMENT", 80, 89], ["Tris-buffered saline", "TREATMENT", 99, 119]]], ["The soluble G protein fraction was separated from the residual suspension by sedimentation of the latter into a 25% sucrose cushion (55,000 \u00d7g, 160 min) and was collected by aspiration of the layer just above the cushion.", [["sucrose", "CHEMICAL", 116, 123], ["sucrose", "CHEMICAL", 116, 123], ["G protein", "GENE_OR_GENE_PRODUCT", 12, 21], ["The soluble G protein fraction", "TREATMENT", 0, 30], ["a 25% sucrose cushion", "TREATMENT", 110, 131], ["residual", "OBSERVATION_MODIFIER", 54, 62], ["suspension", "OBSERVATION_MODIFIER", 63, 73], ["sedimentation", "OBSERVATION_MODIFIER", 77, 90], ["aspiration", "OBSERVATION", 174, 184], ["layer", "OBSERVATION_MODIFIER", 192, 197], ["cushion", "ANATOMY_MODIFIER", 213, 220]]], ["After dialysis against a phosphate buffer (PB, 20 mM pH 7.2), Sephadex G-50 (GE Healthcare, UK) filtration was used to remove excess ampholine.", [["phosphate", "CHEMICAL", 25, 34], ["G-50", "CHEMICAL", 71, 75], ["ampholine", "CHEMICAL", 133, 142], ["phosphate", "CHEMICAL", 25, 34], ["ampholine", "CHEMICAL", 133, 142], ["phosphate", "SIMPLE_CHEMICAL", 25, 34], ["Sephadex G-50", "SIMPLE_CHEMICAL", 62, 75], ["ampholine", "SIMPLE_CHEMICAL", 133, 142], ["dialysis", "TREATMENT", 6, 14], ["a phosphate buffer (PB", "TREATMENT", 23, 45], ["pH", "TEST", 53, 55], ["Sephadex G", "TREATMENT", 62, 72], ["UK) filtration", "TREATMENT", 92, 106], ["excess ampholine", "TREATMENT", 126, 142]]], ["Then the G protein was dialyzed extensively against phosphate buffer (PB, 20 mM pH 7.2) and stored in aliquots at \u221280 \u00b0C until used.", [["phosphate", "CHEMICAL", 52, 61], ["phosphate", "CHEMICAL", 52, 61], ["G protein", "GENE_OR_GENE_PRODUCT", 9, 18], ["phosphate buffer", "SIMPLE_CHEMICAL", 52, 68], ["G protein", "PROTEIN", 9, 18], ["the G protein", "TREATMENT", 5, 18], ["phosphate buffer (PB", "TREATMENT", 52, 72], ["mM pH", "TEST", 77, 82]]], ["Protein concentration was determined using a BCA kit (Pierce, Inc., Rockford, IL).SDS-PAGE and Western blotting ::: Materials and methodsThe purified rabies virus glycoprotein was analyzed by immunoblot analysis.", [["IL", "GENE_OR_GENE_PRODUCT", 78, 80], ["rabies virus glycoprotein", "ORGANISM", 150, 175], ["purified rabies virus glycoprotein", "PROTEIN", 141, 175], ["rabies virus", "SPECIES", 150, 162], ["rabies virus", "SPECIES", 150, 162], ["Protein concentration", "TEST", 0, 21], ["The purified rabies virus glycoprotein", "TREATMENT", 137, 175], ["immunoblot analysis", "TEST", 192, 211], ["rabies virus", "OBSERVATION", 150, 162]]], ["20 \u03bcg of soluble protein was eletrophoresed on 12% denaturing gel and transferred to polyvinylidene difluoride membrane (Bio-rad, USA).", [["polyvinylidene", "CHEMICAL", 85, 99], ["difluoride", "CHEMICAL", 100, 110], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["soluble protein", "PROTEIN", 9, 24], ["soluble protein", "TREATMENT", 9, 24], ["12% denaturing gel", "TREATMENT", 47, 65], ["polyvinylidene difluoride membrane", "TREATMENT", 85, 119]]], ["The membrane was blocked for 2 h at room temperature in 5% non-fat dry milk (NFDM) in PBS (pH 7.4) followed by three washings with PBST (PBS containing 0.05% Tween-20) and incubated with anti-RABV G monoclonal antibodies (MAbG63) for 1 h at 37 \u00b0C. After three additional washes with PBST, the membrane was incubated with HRP-conjugated anti-mouse IgG (GE Healthcare, UK) at a 1:10,000 dilution in PBST for 1 h at room temperature.", [["membrane", "ANATOMY", 4, 12], ["fat dry milk", "ANATOMY", 63, 75], ["membrane", "ANATOMY", 293, 301], ["NFDM", "CHEMICAL", 77, 81], ["Tween-20", "CHEMICAL", 158, 166], ["Tween-20", "CHEMICAL", 158, 166], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["NFDM", "SIMPLE_CHEMICAL", 77, 81], ["Tween-20", "SIMPLE_CHEMICAL", 158, 166], ["membrane", "CELLULAR_COMPONENT", 293, 301], ["HRP", "SIMPLE_CHEMICAL", 321, 324], ["anti-RABV G monoclonal antibodies", "PROTEIN", 187, 220], ["MAbG63", "PROTEIN", 222, 228], ["HRP", "PROTEIN", 321, 324], ["anti-mouse IgG", "PROTEIN", 336, 350], ["anti-RABV", "SPECIES", 187, 196], ["pH", "TEST", 91, 93], ["PBST", "TEST", 131, 135], ["PBS", "TEST", 137, 140], ["anti-RABV G monoclonal antibodies", "TREATMENT", 187, 220], ["PBST", "TREATMENT", 283, 287], ["HRP-conjugated anti-mouse IgG", "TREATMENT", 321, 350]]], ["The membrane was washed three times with PBST and developed by HRP color development kit (Bio-rad, USA) as per the manufacturer's instructions.Preparation of the conjugate pad ::: Materials and methodsColloidal gold particles with a mean diameter of 20 nm were prepared using a method described previously (Peng et al., 2007).", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["HRP", "SIMPLE_CHEMICAL", 63, 66], ["PBST", "TREATMENT", 41, 45], ["methodsColloidal gold particles", "TREATMENT", 194, 225], ["membrane", "OBSERVATION_MODIFIER", 4, 12], ["mean diameter", "OBSERVATION_MODIFIER", 233, 246], ["20 nm", "OBSERVATION_MODIFIER", 250, 255]]], ["Under constant stirring, 1.8 ml of 1% trisodium citrate (w/v) was added rapidly to 100 ml of 0.01% HAuCl4 solution (w/v) at 100 \u00b0C and boiled for 5 min.", [["trisodium citrate", "CHEMICAL", 38, 55], ["HAuCl4", "CHEMICAL", 99, 105], ["trisodium citrate", "CHEMICAL", 38, 55], ["HAuCl4", "CHEMICAL", 99, 105], ["trisodium citrate", "SIMPLE_CHEMICAL", 38, 55], ["HAuCl4", "SIMPLE_CHEMICAL", 99, 105], ["1% trisodium citrate (w/v)", "TREATMENT", 35, 61], ["0.01% HAuCl4 solution", "TREATMENT", 93, 114]]], ["As the resulting colloidal gold cooled gradually to ambient temperature with continuous stirring, the pH was maintained at 8.0 with 0.1 M potassium carbonate.", [["potassium carbonate", "CHEMICAL", 138, 157], ["potassium carbonate", "CHEMICAL", 138, 157], ["colloidal gold", "SIMPLE_CHEMICAL", 17, 31], ["potassium carbonate", "SIMPLE_CHEMICAL", 138, 157], ["continuous stirring", "TREATMENT", 77, 96], ["the pH", "TEST", 98, 104], ["0.1 M potassium carbonate", "TREATMENT", 132, 157]]], ["Sodium azide was added to a final concentration of 0.01% (w/v) before storage at 4 \u00b0C in dark colored glass vessels.Preparation of the conjugate pad ::: Materials and methodsTo prepare colloidal gold-RABV G, 10 ml purified G protein (1.0 mg/ml) was added to 100 ml gold colloidal solution with constant stirring, and incubated for 30 min at room temperature.", [["vessels", "ANATOMY", 108, 115], ["Sodium azide", "CHEMICAL", 0, 12], ["Sodium azide", "CHEMICAL", 0, 12], ["Sodium azide", "SIMPLE_CHEMICAL", 0, 12], ["glass vessels", "MULTI-TISSUE_STRUCTURE", 102, 115], ["RABV", "ORGANISM", 200, 204], ["G", "SIMPLE_CHEMICAL", 205, 206], ["G protein", "GENE_OR_GENE_PRODUCT", 223, 232], ["G protein", "PROTEIN", 223, 232], ["Sodium azide", "TEST", 0, 12], ["storage", "TREATMENT", 70, 77], ["colloidal gold-RABV G", "TREATMENT", 185, 206], ["gold colloidal solution", "TREATMENT", 265, 288], ["glass vessels", "OBSERVATION", 102, 115]]], ["Bovine serum albumin (BSA) was then added to a final concentration of 1% (w/v) to stabilize the conjugate solution, which was then centrifuged at 10,000 \u00d7g for 30 min at 4 \u00b0C. After washing twice in 1% BSA, the colloidal gold-RABV G particulate was suspended in 10 ml 10 mM PBS (pH 8.0) containing 1% BSA, 2% sucrose and 0.01% (w/v) sodium azide, and dispensed onto the fiberglass strips (0.5 cm \u00d7 30 cm, Billerica, MA, USA) at a speed of 50 \u03bcL/cm using a XYZ 3000 Dispensing Platform (Bio-Dot, Irvine, CA, USA) to produce the conjugate pad.", [["serum", "ANATOMY", 7, 12], ["BSA", "CHEMICAL", 22, 25], ["gold-RABV G", "CHEMICAL", 221, 232], ["BSA", "CHEMICAL", 301, 304], ["sucrose", "CHEMICAL", 309, 316], ["sodium azide", "CHEMICAL", 333, 345], ["sucrose", "CHEMICAL", 309, 316], ["sodium azide", "CHEMICAL", 333, 345], ["Bovine", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["albumin", "SIMPLE_CHEMICAL", 13, 20], ["BSA", "SIMPLE_CHEMICAL", 22, 25], ["BSA", "SIMPLE_CHEMICAL", 202, 205], ["colloidal gold", "SIMPLE_CHEMICAL", 211, 225], ["RABV", "ORGANISM", 226, 230], ["G particulate", "SIMPLE_CHEMICAL", 231, 244], ["BSA", "SIMPLE_CHEMICAL", 301, 304], ["sucrose", "SIMPLE_CHEMICAL", 309, 316], ["/v) sodium azide", "SIMPLE_CHEMICAL", 329, 345], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine serum albumin (BSA", "TEST", 0, 25], ["the conjugate solution", "TREATMENT", 92, 114], ["the colloidal gold-RABV G particulate", "TREATMENT", 207, 244], ["pH", "TEST", 279, 281], ["sodium azide", "TREATMENT", 333, 345], ["the fiberglass strips", "TREATMENT", 366, 387], ["a XYZ", "TREATMENT", 454, 459], ["the conjugate pad", "TREATMENT", 523, 540], ["fiberglass", "OBSERVATION", 370, 380]]], ["After drying under vacuum at 4 \u00b0C, the pads were then sealed with a desiccant in plastic bags and stored at 4 \u00b0C.Membrane blotting ::: Materials and methodsOn the 2 cm nitrocellulose membrane (2.0 cm \u00d7 30 cm, Millipore), different working concentrations of staphylococcal protein A (SPA, Sigma\u2013Aldrich, St. Louis, MO, USA) and affinity-purified anti-RABV G monoclonal antibodies were dispensed as test and control lines using the XYZ3000 Dispensing Platform at 1.25 \u03bcL/cm.", [["Membrane", "ANATOMY", 113, 121], ["membrane", "ANATOMY", 183, 191], ["nitrocellulose", "CHEMICAL", 168, 182], ["pads", "ORGANISM_SUBDIVISION", 39, 43], ["staphylococcal protein A", "PROTEIN", 257, 281], ["anti-RABV G monoclonal antibodies", "PROTEIN", 345, 378], ["anti-RABV", "SPECIES", 345, 354], ["vacuum", "TREATMENT", 19, 25], ["the pads", "TREATMENT", 35, 43], ["a desiccant in plastic bags", "TREATMENT", 66, 93], ["Materials", "TEST", 135, 144], ["methodsOn the 2 cm nitrocellulose membrane", "TREATMENT", 149, 191], ["staphylococcal protein", "TEST", 257, 279], ["affinity", "TEST", 327, 335], ["anti-RABV G monoclonal antibodies", "TREATMENT", 345, 378], ["control lines", "TREATMENT", 406, 419], ["vacuum", "OBSERVATION", 19, 25], ["pads", "ANATOMY", 39, 43], ["plastic bags", "OBSERVATION", 81, 93], ["staphylococcal protein", "OBSERVATION", 257, 279]]], ["After being dried at room temperature, they were stored at 4 \u00b0C as described above.Assembly of the immunostrip ::: Materials and methodsSample fiberglass pads were treated with 20 mM phosphate buffer containing 1% PEG, 0.5% Tween-20 and 0.05% sodium azide (pH 7.4), and dried at 37 \u00b0C. Fig. 1provides a schematic diagram of the test strip.", [["phosphate", "CHEMICAL", 183, 192], ["PEG", "CHEMICAL", 214, 217], ["Tween-20", "CHEMICAL", 224, 232], ["sodium azide", "CHEMICAL", 243, 255], ["phosphate", "CHEMICAL", 183, 192], ["PEG", "CHEMICAL", 214, 217], ["Tween-20", "CHEMICAL", 224, 232], ["sodium azide", "CHEMICAL", 243, 255], ["PEG", "SIMPLE_CHEMICAL", 214, 217], ["Tween-20", "SIMPLE_CHEMICAL", 224, 232], ["sodium azide", "SIMPLE_CHEMICAL", 243, 255], ["methodsSample fiberglass pads", "TREATMENT", 129, 158], ["20 mM phosphate buffer", "TREATMENT", 177, 199], ["1% PEG", "TREATMENT", 211, 217], ["0.05% sodium azide", "TREATMENT", 237, 255], ["pH", "TEST", 257, 259], ["the test strip", "TEST", 324, 338]]], ["These were prepared on a 6 cm \u00d7 30 cm adhesive support board upon which were layered, in 1\u20132 mm overlapping positions, a fiberglass sample pad, fiberglass conjugate pad, nitrocellulose membrane, and absorption pad.", [["membrane", "ANATOMY", 185, 193], ["nitrocellulose", "CHEMICAL", 170, 184], ["a 6 cm \u00d7 30 cm adhesive support board", "TREATMENT", 23, 60], ["a fiberglass sample pad", "TREATMENT", 119, 142], ["fiberglass conjugate pad", "TREATMENT", 144, 168], ["nitrocellulose membrane", "TREATMENT", 170, 193], ["absorption pad", "TREATMENT", 199, 213], ["6 cm", "OBSERVATION_MODIFIER", 25, 29], ["layered", "OBSERVATION_MODIFIER", 77, 84], ["fiberglass", "OBSERVATION_MODIFIER", 121, 131], ["fiberglass conjugate", "OBSERVATION", 144, 164]]], ["The assembled boards were then cut into 4 mm wide pieces using a CM 4000 Cutter (Bio-Dot).", [["CM", "DISEASE", 65, 67], ["4 mm wide pieces", "TREATMENT", 40, 56], ["a CM 4000 Cutter", "TREATMENT", 63, 79]]], ["The strip products were mounted in plastic cassettes with windows over the sample pad and the nitrocellulose membrane (Jincanhua Industry, Ltd., Shenzhen, China).", [["membrane", "ANATOMY", 109, 117], ["nitrocellulose", "CHEMICAL", 94, 108], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["The strip products", "TREATMENT", 0, 18], ["the sample pad", "TEST", 71, 85], ["the nitrocellulose membrane", "TREATMENT", 90, 117]]], ["The cassettes were then packaged in plastic bags with desiccant, and stored at 4 \u00b0C until used.Principle of the test ::: Materials and methodsA serum sample (50 \u03bcl) applied to the sample pad migrates into the conjugate pad, where any RABV-specific antibodies react with the colloidal gold-RABV G to form a complex which diffuses across the nitrocellulose membrane and reacts with SPA immobilized on the membrane forming a red-purple line (test line).", [["serum sample", "ANATOMY", 144, 156], ["sample", "ANATOMY", 180, 186], ["membrane", "ANATOMY", 355, 363], ["membrane", "ANATOMY", 403, 411], ["nitrocellulose", "CHEMICAL", 340, 354], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["RABV", "ORGANISM", 234, 238], ["G", "GENE_OR_GENE_PRODUCT", 294, 295], ["membrane", "CELLULAR_COMPONENT", 355, 363], ["SPA", "SIMPLE_CHEMICAL", 380, 383], ["membrane", "CELLULAR_COMPONENT", 403, 411], ["RABV-specific antibodies", "PROTEIN", 234, 258], ["SPA", "PROTEIN", 380, 383], ["red-purple line", "CELL_LINE", 422, 437], ["RABV", "SPECIES", 234, 238], ["RABV", "SPECIES", 289, 293], ["The cassettes", "TREATMENT", 0, 13], ["methodsA serum sample", "TEST", 135, 156], ["the sample pad", "TEST", 176, 190], ["the conjugate pad", "TEST", 205, 222], ["any RABV", "TEST", 230, 238], ["specific antibodies", "TEST", 239, 258], ["the nitrocellulose membrane", "TREATMENT", 336, 363], ["the membrane", "TREATMENT", 399, 411], ["a red-purple line (test line", "TREATMENT", 420, 448], ["plastic bags", "OBSERVATION", 36, 48], ["nitrocellulose membrane", "OBSERVATION", 340, 363], ["red-purple line", "OBSERVATION", 422, 437]]], ["Unreacted gold-RABV G complex migrates further and reacts with the anti-RABV G monoclonal antibodies, forming another red-purple line (control line).", [["red-purple line", "ANATOMY", 118, 133], ["G complex", "GENE_OR_GENE_PRODUCT", 20, 29], ["G complex", "PROTEIN", 20, 29], ["anti-RABV G monoclonal antibodies", "PROTEIN", 67, 100], ["red-purple line", "CELL_LINE", 118, 133], ["RABV", "SPECIES", 15, 19], ["the anti-RABV G monoclonal antibodies", "TREATMENT", 63, 100], ["another red-purple line (control line", "TREATMENT", 110, 147], ["gold", "OBSERVATION_MODIFIER", 10, 14], ["RABV", "OBSERVATION", 15, 19], ["purple line", "OBSERVATION", 122, 133]]], ["The test takes 10\u201315 min to complete, and a sample with a virus neutralizing antibody titer \u2265 0.5 IU/ml will produce two red-purple bands at both the test and control lines, whereas a sample with a titer < 0.5 IU/ml or negative for rabies virus will produce only one band at the control line (Fig. 2).", [["sample", "ANATOMY", 44, 50], ["sample", "ANATOMY", 184, 190], ["rabies virus", "ORGANISM", 232, 244], ["rabies virus", "SPECIES", 232, 244], ["a sample", "TEST", 42, 50], ["a virus neutralizing antibody titer", "TREATMENT", 56, 91], ["two red-purple bands", "PROBLEM", 117, 137], ["the test", "TEST", 146, 154], ["a sample", "TEST", 182, 190], ["a titer", "TEST", 196, 203], ["rabies virus", "PROBLEM", 232, 244]]], ["A clearly visible red-purple band must appear at the control line for the test to be valid.Fluorescent antibody virus neutralization (FAVN) test ::: Materials and methodsVirus neutralizing antibody titers were measured by the FAVN test as described by Cliquet et al. (1998).", [["Virus", "ORGANISM", 170, 175], ["A clearly visible red-purple band", "PROBLEM", 0, 33], ["the test", "TEST", 70, 78], ["Fluorescent antibody virus neutralization", "TEST", 91, 132], ["Virus neutralizing antibody titers", "TEST", 170, 204], ["the FAVN test", "TEST", 222, 235], ["visible", "OBSERVATION_MODIFIER", 10, 17], ["red-purple band", "OBSERVATION", 18, 33]]], ["Serial three-fold dilutions of the tested serum samples and controls were prepared in the microplate wells in 100 \u03bcl volumes.", [["serum samples", "ANATOMY", 42, 55], ["serum samples", "ORGANISM_SUBSTANCE", 42, 55], ["Serial three-fold dilutions", "TREATMENT", 0, 27], ["the tested serum samples", "TEST", 31, 55], ["the microplate wells", "TREATMENT", 86, 106]]], ["100 TCID50 of CVS-11 in 50 \u03bcl were added to each well and incubated at 37 \u00b0C for 60 min.", [["CVS-11", "CHEMICAL", 14, 20], ["CVS", "TEST", 14, 17]]], ["MNA cells (0.2 \u00d7 105 cells in 50 \u03bcl) were added into each well, and the plates were incubated at 37 \u00b0C for 48 h.", [["MNA cells", "ANATOMY", 0, 9], ["cells", "ANATOMY", 21, 26], ["\u03bcl", "ANATOMY", 33, 35], ["MNA cells", "CELL", 0, 9], ["cells", "CELL", 21, 26], ["MNA cells", "CELL_LINE", 0, 9], ["MNA cells", "TEST", 0, 9], ["cells", "TEST", 21, 26], ["the plates", "TEST", 68, 78]]], ["The wells were fixed in ice-cold 80% acetone and stained with FITC-conjugated anti-RABV N antibodies for 0.5 h.", [["acetone", "CHEMICAL", 37, 44], ["acetone", "CHEMICAL", 37, 44], ["FITC", "CHEMICAL", 62, 66], ["acetone", "SIMPLE_CHEMICAL", 37, 44], ["FITC", "SIMPLE_CHEMICAL", 62, 66], ["anti-RABV N antibodies", "SIMPLE_CHEMICAL", 78, 100], ["FITC-conjugated anti-RABV N antibodies", "PROTEIN", 62, 100], ["FITC", "TEST", 62, 66], ["conjugated anti-RABV N antibodies", "TREATMENT", 67, 100]]], ["The plated cells were examined by fluorescent microscope (Olympus Corporation, Tokyo, Japan).", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["plated cells", "CELL_LINE", 4, 16], ["The plated cells", "TREATMENT", 0, 16], ["fluorescent microscope", "TEST", 34, 56], ["plated cells", "OBSERVATION", 4, 16]]], ["Absence and presence of fluorescent foci in the cells was recorded.", [["foci", "ANATOMY", 36, 40], ["cells", "ANATOMY", 48, 53], ["cells", "CELL", 48, 53], ["fluorescent foci in the cells", "PROBLEM", 24, 53], ["fluorescent", "OBSERVATION_MODIFIER", 24, 35], ["foci", "OBSERVATION", 36, 40], ["cells", "ANATOMY", 48, 53]]], ["The 50% endpoint of the antibody was calculated according to the Spearman\u2013K\u00e4rber formula (K\u00e4rber, 1931, Spearman, 1908).", [["the antibody", "TEST", 20, 32]]], ["The values were compared with that of a reference serum (National Institute for Biological Standards and Control, Herts, UK) and normalized to international units (IU/ml).Purification of RABV G protein ::: ResultsIt was found that rabies virus G protein could be isolated from Triton X-100-disrupted rabies virus, without losing its biological and serological properties (Atanasiu et al., 1974, Atanasiu et al., 1976, Cox et al., 1977, Smith et al., 2006).", [["serum", "ANATOMY", 50, 55], ["Triton X-100", "CHEMICAL", 277, 289], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["RABV G protein", "GENE_OR_GENE_PRODUCT", 187, 201], ["rabies virus", "ORGANISM", 231, 243], ["G protein", "GENE_OR_GENE_PRODUCT", 244, 253], ["Triton X-100", "SIMPLE_CHEMICAL", 277, 289], ["rabies virus", "ORGANISM", 300, 312], ["RABV G protein", "PROTEIN", 187, 201], ["rabies virus G protein", "PROTEIN", 231, 253], ["rabies virus", "SPECIES", 231, 243], ["rabies virus", "SPECIES", 300, 312], ["RABV", "SPECIES", 187, 191], ["rabies virus", "SPECIES", 231, 243], ["rabies virus", "SPECIES", 300, 312], ["The values", "TEST", 0, 10], ["Biological Standards", "TEST", 80, 100], ["rabies virus G protein", "TEST", 231, 253], ["Triton X", "TEST", 277, 285], ["disrupted rabies virus", "PROBLEM", 290, 312]]], ["In this study, the inactivated rabies virus was purified by sucrose gradient centrifugation, then soluble glycoprotein was dissociated from the virus by incubation with 1% Triton X-100 and purified by sucrose centrifugation and Sephadex G-50 filtration.", [["sucrose", "CHEMICAL", 60, 67], ["Triton X-100", "CHEMICAL", 172, 184], ["sucrose", "CHEMICAL", 201, 208], ["Sephadex G-50", "CHEMICAL", 228, 241], ["sucrose", "CHEMICAL", 60, 67], ["sucrose", "CHEMICAL", 201, 208], ["rabies virus", "ORGANISM", 31, 43], ["sucrose", "SIMPLE_CHEMICAL", 60, 67], ["Triton X-100", "SIMPLE_CHEMICAL", 172, 184], ["sucrose", "SIMPLE_CHEMICAL", 201, 208], ["soluble glycoprotein", "PROTEIN", 98, 118], ["rabies virus", "SPECIES", 31, 43], ["rabies virus", "SPECIES", 31, 43], ["this study", "TEST", 3, 13], ["the inactivated rabies virus", "PROBLEM", 15, 43], ["sucrose gradient centrifugation", "TREATMENT", 60, 91], ["soluble glycoprotein", "TREATMENT", 98, 118], ["1% Triton", "TREATMENT", 169, 178], ["sucrose centrifugation", "TREATMENT", 201, 223], ["Sephadex G", "TREATMENT", 228, 238]]], ["About 12% of total protein was recovered after purification.", [["total protein", "TEST", 13, 26]]], ["To characterize the purified protein, purity and biological activity of the rabies virus G proteins were analyzed by SDS-PAGE (Fig. 3A) and Western blotting (Fig. 3B).", [["rabies virus G", "ORGANISM", 76, 90], ["rabies virus G proteins", "PROTEIN", 76, 99], ["rabies virus", "SPECIES", 76, 88], ["rabies virus", "SPECIES", 76, 88], ["the purified protein", "TEST", 16, 36], ["the rabies virus G proteins", "TREATMENT", 72, 99]]], ["As shown in Fig. 3A, the purified proteins displayed a dominant protein band that represented approximately 95% of the purified protein.", [["purified proteins", "PROTEIN", 25, 42], ["purified protein", "PROTEIN", 119, 135], ["the purified proteins", "TEST", 21, 42], ["a dominant protein band", "PROBLEM", 53, 76], ["dominant", "OBSERVATION_MODIFIER", 55, 63], ["protein band", "OBSERVATION", 64, 76]]], ["Western blotting using anti-RABV G monoclonal antibody identified the purified rabies virus G proteins.", [["rabies virus G proteins", "GENE_OR_GENE_PRODUCT", 79, 102], ["anti-RABV", "PROTEIN", 23, 32], ["G monoclonal antibody", "PROTEIN", 33, 54], ["purified rabies virus G proteins", "PROTEIN", 70, 102], ["rabies virus", "SPECIES", 79, 91], ["anti-RABV", "TREATMENT", 23, 32], ["G monoclonal antibody", "TEST", 33, 54], ["monoclonal antibody", "OBSERVATION", 35, 54]]], ["The data showed that the rabies virus G proteins were purified highly and not degraded during the purification procedure.Determination of working concentrations of captured reagents for immobilization ::: ResultsStaphylococcal protein A (SPA) and affinity-purified anti-RABV G monoclonal antibodies were diluted to 1.0, 1.5, 2.0, and 2.5 mg/ml with 20 mM PBS (pH 7.4).", [["rabies virus", "ORGANISM", 25, 37], ["G", "GENE_OR_GENE_PRODUCT", 38, 39], ["ResultsStaphylococcal protein A", "GENE_OR_GENE_PRODUCT", 205, 236], ["SPA", "GENE_OR_GENE_PRODUCT", 238, 241], ["rabies virus G proteins", "PROTEIN", 25, 48], ["ResultsStaphylococcal protein A", "PROTEIN", 205, 236], ["SPA", "PROTEIN", 238, 241], ["anti-RABV G monoclonal antibodies", "PROTEIN", 265, 298], ["rabies virus", "SPECIES", 25, 37], ["anti-RABV", "SPECIES", 265, 274], ["The data", "TEST", 0, 8], ["the rabies virus G proteins", "TEST", 21, 48], ["the purification procedure", "TREATMENT", 94, 120], ["ResultsStaphylococcal protein", "TEST", 205, 234], ["affinity", "TEST", 247, 255], ["anti-RABV", "TEST", 265, 274], ["monoclonal antibodies", "TEST", 277, 298], ["20 mM PBS", "TEST", 349, 358], ["pH", "TEST", 360, 362]]], ["The various working concentrations were then dispensed onto nitrocellulose membrane for assembly of ICTS.", [["membrane", "ANATOMY", 75, 83], ["nitrocellulose", "CHEMICAL", 60, 74], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["nitrocellulose membrane", "TREATMENT", 60, 83]]], ["The optimal concentration of SPA was achieved by testing the ICTS with different concentrations against 0.5 IU/ml WHO standard serum, and selecting the minimum concentration that produced a detectable line.", [["serum", "ANATOMY", 127, 132], ["SPA", "SIMPLE_CHEMICAL", 29, 32], ["ICTS", "SIMPLE_CHEMICAL", 61, 65], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["detectable line", "OBSERVATION", 190, 205]]], ["The result showed that the optimal concentration of SPA that produced a detectable line with 0.5 IU/ml WHO standard serum but not reacted with sera of virus neutralizing antibody titers < 0.5 IU/ml, or negative sera, was 1.5 mg/ml.", [["serum", "ANATOMY", 116, 121], ["sera", "ANATOMY", 143, 147], ["sera", "ANATOMY", 211, 215], ["SPA", "SIMPLE_CHEMICAL", 52, 55], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["sera", "ORGANISM_SUBSTANCE", 143, 147], ["sera", "ORGANISM_SUBSTANCE", 211, 215], ["standard serum", "TEST", 107, 121], ["sera of virus neutralizing antibody titers", "TEST", 143, 185]]], ["The optimal concentration of anti-RABV G monoclonal antibody was determined based on the red color of the control line both for positive and negative samples.", [["samples", "ANATOMY", 150, 157], ["anti-RABV G monoclonal antibody", "PROTEIN", 29, 60], ["anti-RABV", "SPECIES", 29, 38], ["anti-RABV G monoclonal antibody", "TREATMENT", 29, 60], ["the red color", "TEST", 85, 98]]], ["Finally, the optimal concentrations of SPA and affinity-purified anti-RABV G monoclonal antibody for immobilization were 1.5 and 1.0 mg/ml, respectively (data not shown).Specificity of the ICTS ::: ResultsThe specificity of the ICTS was demonstrated by testing 185 sera from dogs, cats, rabbits and mice that had never been vaccinated, 115 different serum samples derived from dogs vaccinated with non-RABV pathogens (CDV, CPV, CAV, CCV, CPIV), different commercial rabies vaccines or virus strains maintained in the laboratory.", [["sera", "ANATOMY", 265, 269], ["serum samples", "ANATOMY", 350, 363], ["SPA", "SIMPLE_CHEMICAL", 39, 42], ["ICTS", "CANCER", 228, 232], ["sera", "ORGANISM_SUBSTANCE", 265, 269], ["dogs", "ORGANISM", 275, 279], ["cats", "ORGANISM", 281, 285], ["rabbits", "ORGANISM", 287, 294], ["mice", "ORGANISM", 299, 303], ["serum samples", "ORGANISM_SUBSTANCE", 350, 363], ["dogs", "ORGANISM", 377, 381], ["CDV", "ORGANISM", 418, 421], ["CPV", "ORGANISM", 423, 426], ["CAV", "ORGANISM", 428, 431], ["CCV", "ORGANISM", 433, 436], ["rabies", "ORGANISM", 466, 472], ["SPA", "PROTEIN", 39, 42], ["anti-RABV G monoclonal antibody", "PROTEIN", 65, 96], ["dogs", "SPECIES", 275, 279], ["cats", "SPECIES", 281, 285], ["rabbits", "SPECIES", 287, 294], ["mice", "SPECIES", 299, 303], ["dogs", "SPECIES", 377, 381], ["rabbits", "SPECIES", 287, 294], ["mice", "SPECIES", 299, 303], ["non-RABV", "SPECIES", 398, 406], ["CDV", "SPECIES", 418, 421], ["CPV", "SPECIES", 423, 426], ["CAV", "SPECIES", 428, 431], ["CCV", "SPECIES", 433, 436], ["CPIV", "SPECIES", 438, 442], ["rabies", "SPECIES", 466, 472], ["SPA and affinity", "TREATMENT", 39, 55], ["purified anti-RABV G monoclonal antibody", "TREATMENT", 56, 96], ["immobilization", "TEST", 101, 115], ["testing", "TEST", 253, 260], ["cats", "TEST", 281, 285], ["serum samples", "TEST", 350, 363], ["dogs vaccinated", "TREATMENT", 377, 392], ["non-RABV pathogens", "PROBLEM", 398, 416], ["CDV", "PROBLEM", 418, 421], ["CPV", "PROBLEM", 423, 426], ["CAV", "TREATMENT", 428, 431], ["CPIV", "TREATMENT", 438, 442], ["different commercial rabies vaccines", "TREATMENT", 445, 481], ["virus strains", "PROBLEM", 485, 498], ["CAV", "ANATOMY", 428, 431]]], ["The results were compared with the same samples analyzed by FAVN tests.", [["samples", "ANATOMY", 40, 47], ["the same samples", "TEST", 31, 47], ["FAVN tests", "TEST", 60, 70]]], ["All serum samples derived from non-immunized dogs, cats, rabbits and mice, and sera from dogs immunized with pathogens other than rabies virus were found to be negative for anti-RABV antibodies by both ICTS and FAVN tests.", [["serum samples", "ANATOMY", 4, 17], ["sera", "ANATOMY", 79, 83], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["dogs", "ORGANISM", 45, 49], ["cats", "ORGANISM", 51, 55], ["rabbits", "ORGANISM", 57, 64], ["mice", "ORGANISM", 69, 73], ["sera", "ORGANISM_SUBSTANCE", 79, 83], ["dogs", "ORGANISM", 89, 93], ["rabies virus", "ORGANISM", 130, 142], ["anti-RABV antibodies", "PROTEIN", 173, 193], ["dogs", "SPECIES", 45, 49], ["cats", "SPECIES", 51, 55], ["rabbits", "SPECIES", 57, 64], ["mice", "SPECIES", 69, 73], ["dogs", "SPECIES", 89, 93], ["rabies virus", "SPECIES", 130, 142], ["rabbits", "SPECIES", 57, 64], ["mice", "SPECIES", 69, 73], ["rabies virus", "SPECIES", 130, 142], ["anti-RABV", "SPECIES", 173, 182], ["All serum samples", "TEST", 0, 17], ["non-immunized dogs", "TREATMENT", 31, 49], ["cats", "TEST", 51, 55], ["sera", "TREATMENT", 79, 83], ["pathogens", "PROBLEM", 109, 118], ["rabies virus", "PROBLEM", 130, 142], ["anti-RABV antibodies", "PROBLEM", 173, 193], ["FAVN tests", "TEST", 211, 221]]], ["Visually, the tested samples appeared identical to the blank control, with only one red-purple band at the control line.", [["samples", "ANATOMY", 21, 28], ["the tested samples", "TEST", 10, 28], ["one red-purple band", "TREATMENT", 80, 99], ["red-purple band", "OBSERVATION", 84, 99], ["control line", "OBSERVATION", 107, 119]]], ["All serum samples from dogs with virus neutralizing antibody titers \u2265 0.5 IU/ml determined by FAVN tests produced two bands by ICTS (Fig. 4).", [["serum samples", "ANATOMY", 4, 17], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["dogs", "ORGANISM", 23, 27], ["FAVN", "PROTEIN", 94, 98], ["dogs", "SPECIES", 23, 27], ["All serum samples", "TEST", 0, 17], ["dogs", "TEST", 23, 27], ["virus neutralizing antibody titers", "TEST", 33, 67], ["FAVN tests", "TEST", 94, 104]]], ["The ICTS was specific for sera positive for rabies virus and did not cross-react with other na\u00efve animal sera or sera from animals immunized with other pathogens.Sensitivity of the ICTS ::: ResultsSera positive for rabies virus from dogs immunized with various rabies vaccines were tested by ICTS with 3 different operators.", [["sera", "ANATOMY", 26, 30], ["sera", "ANATOMY", 105, 109], ["sera", "ANATOMY", 113, 117], ["rabies virus", "DISEASE", 215, 227], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["rabies virus", "ORGANISM", 44, 56], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["sera", "ORGANISM_SUBSTANCE", 113, 117], ["ResultsSera", "GENE_OR_GENE_PRODUCT", 190, 201], ["rabies virus", "ORGANISM", 215, 227], ["dogs", "ORGANISM", 233, 237], ["rabies", "ORGANISM", 261, 267], ["rabies virus", "SPECIES", 215, 227], ["dogs", "SPECIES", 233, 237], ["rabies virus", "SPECIES", 44, 56], ["rabies virus", "SPECIES", 215, 227], ["rabies", "SPECIES", 261, 267], ["sera", "TEST", 26, 30], ["rabies virus", "PROBLEM", 44, 56], ["other pathogens", "PROBLEM", 146, 161], ["ResultsSera", "TEST", 190, 201], ["rabies virus", "PROBLEM", 215, 227], ["dogs immunized", "TREATMENT", 233, 247], ["various rabies vaccines", "TREATMENT", 253, 276]]], ["When the virus neutralizing antibody titer of the serum samples was \u22650.5 IU/ml as determined by FAVN tests, the results by ICTS were all positive.", [["serum samples", "ANATOMY", 50, 63], ["serum samples", "ORGANISM_SUBSTANCE", 50, 63], ["the virus neutralizing antibody titer", "TEST", 5, 42], ["the serum samples", "TEST", 46, 63], ["FAVN tests", "TEST", 96, 106]]], ["The results were negative by ICTS when the serum samples were negative or with a titer < 0.5 IU/ml (Table 1).", [["serum samples", "ANATOMY", 43, 56], ["serum samples", "ORGANISM_SUBSTANCE", 43, 56], ["the serum samples", "TEST", 39, 56], ["a titer", "TEST", 79, 86]]], ["The sensitivity of the ICTS was also demonstrated by testing 152 selected serum samples with titers ranging from 0.2 IU/ml to 0.8 IU/ml as determined by FAVN tests (Table 2).", [["serum samples", "ANATOMY", 74, 87], ["serum samples", "ORGANISM_SUBSTANCE", 74, 87], ["the ICTS", "TEST", 19, 27], ["testing", "TEST", 53, 60], ["serum samples", "TEST", 74, 87], ["titers", "TEST", 93, 99], ["FAVN tests", "TEST", 153, 163]]], ["Results showed that of the 108 sera with titers \u2265 0.5 IU/ml, 100 (92.6%) produced a distinct band on the test line, and 8 (7.4%) gave a negative response.", [["sera", "ANATOMY", 31, 35], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["titers", "TEST", 41, 47], ["a distinct band", "PROBLEM", 82, 97], ["the test line", "TEST", 101, 114]]], ["Of the 8 sera giving a negative result, all of them had VNA titer ranging from 0.5 IU/ml to 0.7 IU/ml.Correlation between ICTS and FAVN in clinical samples ::: ResultsA total of 756 clinical serum samples selected at random from 10 different provinces were tested by ICTS, and the results were compared with those obtained by FAVN tests (Table 3).", [["sera", "ANATOMY", 9, 13], ["serum samples", "ANATOMY", 191, 204], ["sera", "ORGANISM_SUBSTANCE", 9, 13], ["VNA", "GENE_OR_GENE_PRODUCT", 56, 59], ["serum samples", "ORGANISM_SUBSTANCE", 191, 204], ["VNA titer", "TEST", 56, 65], ["clinical serum samples", "TEST", 182, 204], ["FAVN tests", "TEST", 326, 336]]], ["Of the total 756 serum samples, 138 negative samples as determined by FAVN tests were also confirmed to be negative by ICTS.", [["serum samples", "ANATOMY", 17, 30], ["samples", "ANATOMY", 45, 52], ["serum samples", "ORGANISM_SUBSTANCE", 17, 30], ["FAVN", "PROTEIN", 70, 74], ["serum samples", "TEST", 17, 30], ["FAVN tests", "TEST", 70, 80]]], ["Of 252 sera with virus neutralizing antibody titers < 0.5 IU/ml, 245 sera were negative by the ICTS with a consistency of 97.2%, and all 7 sera with conflicting results between the two tests had FAVN titers ranging from 0.45 IU/ml to 0.49 IU/ml.", [["sera", "ANATOMY", 7, 11], ["sera", "ANATOMY", 69, 73], ["sera", "ANATOMY", 139, 143], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["sera", "ORGANISM_SUBSTANCE", 69, 73], ["sera", "ORGANISM_SUBSTANCE", 139, 143], ["FAVN", "GENE_OR_GENE_PRODUCT", 195, 199], ["sera", "TEST", 7, 11], ["virus neutralizing antibody titers", "TEST", 17, 51], ["IU/ml", "TEST", 58, 63], ["sera", "TEST", 69, 73], ["a consistency", "TEST", 105, 118], ["the two tests", "TEST", 177, 190], ["FAVN titers", "TEST", 195, 206]]], ["Of 366 sera with virus neutralizing antibody titers \u2265 0.5 IU/ml, 331 sera were positive by the ICTS with a consistency of 90.4%.", [["sera", "ANATOMY", 7, 11], ["sera", "ANATOMY", 69, 73], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["sera", "ORGANISM_SUBSTANCE", 69, 73], ["sera", "TEST", 7, 11], ["virus neutralizing antibody titers", "TEST", 17, 51], ["sera", "TEST", 69, 73]]], ["There was an excellent agreement (kappa = 0.888) between ICTS and FAVN tests.Storage life and reproducibility ::: ResultsImmunochromatographic strips packaged in a plastic bag with a desiccant stored at 4 \u00b0C or at ambient temperature for varying times up to 24 months were tested for specificity and sensitivity.", [["kappa", "TEST", 34, 39], ["ICTS and FAVN tests", "TEST", 57, 76], ["ResultsImmunochromatographic strips", "TREATMENT", 114, 149], ["a plastic bag", "TREATMENT", 162, 175], ["sensitivity", "TEST", 300, 311], ["plastic bag", "OBSERVATION", 164, 175]]], ["All test results were identical by using the strips stored from 3 to 12 months, with all known serapositive samples being positive and all known VNA-negative sera being negative.", [["samples", "ANATOMY", 108, 115], ["sera", "ANATOMY", 158, 162], ["samples", "CANCER", 108, 115], ["VNA", "GENE_OR_GENE_PRODUCT", 145, 148], ["sera", "ORGANISM_SUBSTANCE", 158, 162], ["VNA", "PROTEIN", 145, 148], ["All test", "TEST", 0, 8], ["all known serapositive samples", "PROBLEM", 85, 115], ["VNA", "TEST", 145, 148]]], ["After 15 months of storage at ambient temperature, the sensitivity of the strips decreased slightly as the known positives with titers between 0.50 and 1.0 IU/ml produced negative results (15.8%).", [["ambient temperature", "TEST", 30, 49], ["the sensitivity", "TEST", 51, 66], ["the strips", "TEST", 70, 80], ["titers", "TEST", 128, 134]]], ["However, sera with VNA titer > 1.0 IU/ml or < 0.5 IU/ml, or negative sera were still tested consistently with the FAVN tests.", [["sera", "ANATOMY", 9, 13], ["sera", "ANATOMY", 69, 73], ["sera", "ORGANISM_SUBSTANCE", 9, 13], ["VNA", "GENE_OR_GENE_PRODUCT", 19, 22], ["sera", "ORGANISM_SUBSTANCE", 69, 73], ["sera", "TEST", 9, 13], ["VNA titer", "TEST", 19, 28], ["the FAVN tests", "TEST", 110, 124]]], ["The strips stored at 4 \u00b0C for 18 months gave consistent results except that 12.6% of those in the range 0.50\u20131.0 IU/ml were tested as negative.", [["The strips", "TREATMENT", 0, 10], ["IU/ml", "TEST", 113, 118]]], ["All samples were tested on strips from three separate batches, showing that there was complete reproducibility between batches.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["complete reproducibility between batches", "PROBLEM", 86, 126], ["reproducibility", "OBSERVATION_MODIFIER", 95, 110]]], ["After 24 months, most of the ICTS stored at either 4 \u00b0C or at ambient temperature showed the same appearance as before, only 1.8% had not been dehumidified properly.", [["ICTS", "DISEASE", 29, 33], ["ambient temperature", "TEST", 62, 81]]], ["Therefore, the results showed that sealed strips could be stored for at least 15 months at 4 \u00b0C or 12 months at ambient temperature with only a slight loss of sensitivity.DiscussionThe present study describes a new approach for determining the virus-neutralizing antibodies against rabies virus by ICTS, a technique that has been used for detecting many other antigens and virus-specific antibodies.", [["rabies virus", "DISEASE", 282, 294], ["rabies virus", "ORGANISM", 282, 294], ["virus-neutralizing antibodies", "PROTEIN", 244, 273], ["antigens", "PROTEIN", 360, 368], ["virus-specific antibodies", "PROTEIN", 373, 398], ["rabies virus", "SPECIES", 282, 294], ["rabies virus", "SPECIES", 282, 294], ["sealed strips", "TREATMENT", 35, 48], ["a slight loss of sensitivity", "PROBLEM", 142, 170], ["a new approach", "TREATMENT", 209, 223], ["the virus", "PROBLEM", 240, 249], ["neutralizing antibodies", "TREATMENT", 250, 273], ["rabies virus", "PROBLEM", 282, 294], ["a technique", "TREATMENT", 304, 315], ["many other antigens", "PROBLEM", 349, 368], ["virus", "PROBLEM", 373, 378], ["slight", "OBSERVATION_MODIFIER", 144, 150], ["loss", "OBSERVATION", 151, 155]]], ["The cut-off value of the ICTS was 0.5 IU/ml, and with the FAVN test used as a reference test, the ICTS had high specificity (98.2%) and sensitivity (90.4%).", [["the FAVN test", "TEST", 54, 67], ["a reference test", "TEST", 76, 92], ["the ICTS", "TEST", 94, 102], ["sensitivity", "TEST", 136, 147]]], ["There was an excellent agreement between the results obtained by FAVN test and ICTS (kappa = 0.888) for clinical samples.DiscussionThe sensitivity and specificity of ICTS is dependent largely on the antigen used in the test strip.", [["samples", "ANATOMY", 113, 120], ["kappa", "TEST", 85, 90], ["clinical samples", "TEST", 104, 120], ["The sensitivity", "TEST", 131, 146], ["the test strip", "TEST", 215, 229]]], ["Rabies virus glycoprotein is the only structural protein of the virus that induces the formation of virus-neutralizing antibodies, which confer immunity to animals.", [["Rabies virus", "ORGANISM", 0, 12], ["Rabies virus glycoprotein", "PROTEIN", 0, 25], ["structural protein", "PROTEIN", 38, 56], ["virus-neutralizing antibodies", "PROTEIN", 100, 129], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus glycoprotein", "PROBLEM", 0, 25], ["the virus", "PROBLEM", 60, 69], ["virus", "PROBLEM", 100, 105], ["neutralizing antibodies", "PROBLEM", 106, 129], ["virus", "OBSERVATION", 100, 105]]], ["The protective activity was shown to be associated only with the G protein and not with the membrane associated protein M and P, although they contain residual traces of G protein (Cox et al., 1977).", [["membrane", "ANATOMY", 92, 100], ["G protein", "GENE_OR_GENE_PRODUCT", 65, 74], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["G protein", "GENE_OR_GENE_PRODUCT", 170, 179], ["G protein", "PROTEIN", 65, 74], ["membrane associated protein M and P", "PROTEIN", 92, 127], ["G protein", "PROTEIN", 170, 179], ["the G protein", "TREATMENT", 61, 74]]], ["Competitive ELISA that utilizes a cell line stably expressing the rabies virus G protein as the coating antigen has higher specificity and sensitivity than that of ELISA based on whole rabies virus antigen (Bahloul et al., 2005, Servat and Cliquet, 2006).", [["cell line", "ANATOMY", 34, 43], ["cell line", "CELL", 34, 43], ["rabies virus G", "ORGANISM", 66, 80], ["rabies virus", "ORGANISM", 185, 197], ["cell line", "CELL_LINE", 34, 43], ["rabies virus G protein", "PROTEIN", 66, 88], ["rabies virus", "SPECIES", 66, 78], ["rabies virus", "SPECIES", 185, 197], ["rabies virus", "SPECIES", 66, 78], ["rabies virus", "SPECIES", 185, 197], ["Competitive ELISA", "PROBLEM", 0, 17], ["a cell line", "TREATMENT", 32, 43], ["the rabies virus G protein", "TREATMENT", 62, 88], ["the coating antigen", "TEST", 92, 111], ["ELISA", "TEST", 164, 169], ["whole rabies virus antigen", "TEST", 179, 205]]], ["Also, there is an excellent agreement between the FAVN test and competitive ELISA.", [["the FAVN test", "TEST", 46, 59]]], ["In the study presented here, the virus was cultured at 32 \u00b0C for 4 d, and this was sufficient to obtain more G protein than virus grown at 37 \u00b0C. In order to reduce the false-positive results, sucrose gradient centrifugation was used to purify the virus.", [["sucrose", "CHEMICAL", 193, 200], ["sucrose", "CHEMICAL", 193, 200], ["G protein", "GENE_OR_GENE_PRODUCT", 109, 118], ["sucrose", "SIMPLE_CHEMICAL", 193, 200], ["G protein", "PROTEIN", 109, 118], ["the study", "TEST", 3, 12], ["the virus", "PROBLEM", 29, 38], ["sucrose gradient centrifugation", "TREATMENT", 193, 224], ["the virus", "PROBLEM", 244, 253]]], ["Subsequently the G protein was dissociated from the purified virus by incubation with Triton X-100, which could have a higher biological and protective activity than that solubilized by deoxycholate or by Nonidet P-40 (Cox et al., 1977).", [["Triton X-100", "CHEMICAL", 86, 98], ["deoxycholate", "CHEMICAL", 186, 198], ["Nonidet P-40", "CHEMICAL", 205, 217], ["Triton X-100", "CHEMICAL", 86, 98], ["deoxycholate", "CHEMICAL", 186, 198], ["Nonidet P-40", "CHEMICAL", 205, 217], ["G protein", "GENE_OR_GENE_PRODUCT", 17, 26], ["Triton X-100", "SIMPLE_CHEMICAL", 86, 98], ["deoxycholate", "SIMPLE_CHEMICAL", 186, 198], ["Nonidet P-40", "SIMPLE_CHEMICAL", 205, 217], ["G protein", "PROTEIN", 17, 26], ["the G protein", "TEST", 13, 26], ["Triton", "TREATMENT", 86, 92], ["deoxycholate", "TREATMENT", 186, 198]]], ["The sensitivity and specificity of ICTS in this study did not produce any difference between serum samples derived from dogs vaccinated with inactivated Pasteur virus (PV) strain, inactivated Evelyn-Rokitnicki-Abelseth (ERA) strain, Flury-LEP vaccines and commercial vaccines (Intervet Nobivac) (Table 1), and there was also an excellent correlation with the FAVN test.", [["serum samples", "ANATOMY", 93, 106], ["serum samples", "ORGANISM_SUBSTANCE", 93, 106], ["dogs", "ORGANISM", 120, 124], ["Pasteur virus", "ORGANISM", 153, 166], ["Abelseth", "SIMPLE_CHEMICAL", 210, 218], ["dogs", "SPECIES", 120, 124], ["Pasteur virus", "SPECIES", 153, 166], ["Pasteur virus", "SPECIES", 153, 166], ["PV", "SPECIES", 168, 170], ["Evelyn-Rokitnicki-Abelseth", "SPECIES", 192, 218], ["The sensitivity", "TEST", 0, 15], ["this study", "TEST", 43, 53], ["serum samples", "TEST", 93, 106], ["dogs vaccinated", "TREATMENT", 120, 135], ["inactivated Pasteur virus (PV) strain", "PROBLEM", 141, 178], ["Flury-LEP vaccines", "TREATMENT", 233, 251], ["commercial vaccines", "TREATMENT", 256, 275], ["Intervet Nobivac)", "TREATMENT", 277, 294], ["the FAVN test", "TEST", 355, 368]]], ["This might be attributed to using the same strain of RABV (CVS-11) as an antigen in both of the ICTS and FAVN test.DiscussionStaphylococcal protein A (SPA) is bacterial proteins that bind with high specificity to mammalian immunoglobulins, and is used commonly to purify, immobilize or detect immunoglobulins.", [["RABV", "ORGANISM", 53, 57], ["CVS-11", "ORGANISM", 59, 65], ["Staphylococcal protein A", "GENE_OR_GENE_PRODUCT", 125, 149], ["SPA", "GENE_OR_GENE_PRODUCT", 151, 154], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 223, 238], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 293, 308], ["Staphylococcal protein A", "PROTEIN", 125, 149], ["SPA", "PROTEIN", 151, 154], ["bacterial proteins", "PROTEIN", 159, 177], ["mammalian immunoglobulins", "PROTEIN", 213, 238], ["immunoglobulins", "PROTEIN", 293, 308], ["RABV", "SPECIES", 53, 57], ["CVS", "TEST", 59, 62], ["an antigen", "TEST", 70, 80], ["the ICTS", "TEST", 92, 100], ["FAVN test", "TEST", 105, 114], ["Staphylococcal protein", "TEST", 125, 147], ["bacterial proteins", "PROBLEM", 159, 177], ["mammalian immunoglobulins", "TEST", 213, 238], ["immunoglobulins", "PROBLEM", 293, 308]]], ["However, they have different affinities to immunoglobulin with different isotypes.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 43, 57], ["immunoglobulin", "PROTEIN", 43, 57], ["immunoglobulin", "TREATMENT", 43, 57], ["different isotypes", "PROBLEM", 63, 81]]], ["Also, the binding capacity with immunoglobulin of SPA differs between mammalian species.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 32, 46], ["SPA", "GENE_OR_GENE_PRODUCT", 50, 53], ["immunoglobulin", "PROTEIN", 32, 46], ["SPA", "PROTEIN", 50, 53], ["the binding capacity", "PROBLEM", 6, 26], ["immunoglobulin of SPA", "TREATMENT", 32, 53], ["mammalian species", "PROBLEM", 70, 87], ["mammalian species", "OBSERVATION", 70, 87]]], ["In this study, SPA was immobilized on the membrane and used as the test line, and it showed high affinity to serum samples from dogs.", [["membrane", "ANATOMY", 42, 50], ["serum samples", "ANATOMY", 109, 122], ["SPA", "SIMPLE_CHEMICAL", 15, 18], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["serum samples", "ORGANISM_SUBSTANCE", 109, 122], ["dogs", "ORGANISM", 128, 132], ["dogs", "SPECIES", 128, 132], ["this study", "TEST", 3, 13], ["the membrane", "TREATMENT", 38, 50], ["the test line", "TEST", 63, 76], ["high affinity", "PROBLEM", 92, 105], ["serum samples", "TEST", 109, 122]]], ["In addition, the ICTS can also be used to detect serum samples positive for rabies virus derived from humans, cats, rabbits and mice, but the sensitivity varies (data not shown).", [["serum samples", "ANATOMY", 49, 62], ["serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["rabies virus", "ORGANISM", 76, 88], ["humans", "ORGANISM", 102, 108], ["cats", "ORGANISM", 110, 114], ["rabbits", "ORGANISM", 116, 123], ["mice", "ORGANISM", 128, 132], ["ICTS", "PROTEIN", 17, 21], ["humans", "SPECIES", 102, 108], ["cats", "SPECIES", 110, 114], ["rabbits", "SPECIES", 116, 123], ["mice", "SPECIES", 128, 132], ["rabies virus", "SPECIES", 76, 88], ["humans", "SPECIES", 102, 108], ["rabbits", "SPECIES", 116, 123], ["mice", "SPECIES", 128, 132], ["serum samples", "TEST", 49, 62], ["rabies virus", "PROBLEM", 76, 88], ["the sensitivity varies", "TEST", 138, 160]]], ["The ICTS showed higher sensitivity when detecting sera from canine, human and rabbit, and a relatively lower sensitivity for detection of mouse and cat sera.", [["sera", "ANATOMY", 50, 54], ["sera", "ANATOMY", 152, 156], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["canine", "ORGANISM", 60, 66], ["human", "ORGANISM", 68, 73], ["rabbit", "ORGANISM", 78, 84], ["mouse", "ORGANISM", 138, 143], ["cat", "ORGANISM", 148, 151], ["sera", "ORGANISM_SUBSTANCE", 152, 156], ["canine", "SPECIES", 60, 66], ["human", "SPECIES", 68, 73], ["rabbit", "SPECIES", 78, 84], ["mouse", "SPECIES", 138, 143], ["cat", "SPECIES", 148, 151], ["canine", "SPECIES", 60, 66], ["human", "SPECIES", 68, 73], ["rabbit", "SPECIES", 78, 84], ["mouse", "SPECIES", 138, 143], ["cat", "SPECIES", 148, 151], ["The ICTS", "TEST", 0, 8], ["higher sensitivity", "PROBLEM", 16, 34], ["mouse and cat sera", "TEST", 138, 156]]], ["Therefore, the ICTS may also be useful in serosurveillance with these species.DiscussionThe ICTS has been validated by comparing the results of 756 clinical serum samples with those obtained using the FAVN test.", [["serum samples", "ANATOMY", 157, 170], ["serum samples", "ORGANISM_SUBSTANCE", 157, 170], ["these species", "PROBLEM", 64, 77], ["clinical serum samples", "TEST", 148, 170], ["the FAVN test", "TEST", 197, 210]]], ["False-negative results occurred with the ICTS test for samples possessing virus neutralizing antibodies \u22650.5 IU/ml, which implies that the sera did not have an adequate level of neutralizing antibody.", [["samples", "ANATOMY", 55, 62], ["sera", "ANATOMY", 139, 143], ["sera", "ORGANISM_SUBSTANCE", 139, 143], ["virus neutralizing antibodies", "PROTEIN", 74, 103], ["neutralizing antibody", "PROTEIN", 178, 199], ["the ICTS test", "TEST", 37, 50], ["samples possessing virus neutralizing antibodies", "TEST", 55, 103], ["the sera", "TEST", 135, 143], ["neutralizing antibody", "PROBLEM", 178, 199], ["negative", "OBSERVATION", 6, 14], ["neutralizing antibody", "OBSERVATION", 178, 199]]], ["The isotype of RABV-specific antibody from those serum samples was detected by ELISA, and it was shown that the isotype of those antibodies was IgM, but not IgG (data not shown).", [["serum samples", "ANATOMY", 49, 62], ["RABV", "ORGANISM", 15, 19], ["serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["IgM", "GENE_OR_GENE_PRODUCT", 144, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 157, 160], ["RABV-specific antibody", "PROTEIN", 15, 37], ["antibodies", "PROTEIN", 129, 139], ["IgM", "PROTEIN", 144, 147], ["IgG", "PROTEIN", 157, 160], ["RABV", "SPECIES", 15, 19], ["RABV", "TEST", 15, 19], ["specific antibody", "TEST", 20, 37], ["those serum samples", "TEST", 43, 62], ["ELISA", "TEST", 79, 84], ["those antibodies", "TEST", 123, 139], ["IgM", "TEST", 144, 147], ["IgG", "TEST", 157, 160]]], ["Since SPA has higher binding affinity with IgG than IgM, this may explain why those samples did not produce a positive result when tested by ICTS.", [["samples", "ANATOMY", 84, 91], ["SPA", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgM", "GENE_OR_GENE_PRODUCT", 52, 55], ["SPA", "PROTEIN", 6, 9], ["IgG", "PROTEIN", 43, 46], ["IgM", "PROTEIN", 52, 55], ["higher binding affinity", "PROBLEM", 14, 37], ["IgG than IgM", "PROBLEM", 43, 55]]], ["Among 390 samples with virus neutralizing antibody titer < 0.5 IU/ml, only 7 samples were positive by ICTS.", [["samples", "ANATOMY", 10, 17], ["samples", "ANATOMY", 77, 84], ["samples", "CANCER", 10, 17], ["samples", "CANCER", 77, 84], ["virus neutralizing antibody titer", "TEST", 23, 56]]], ["However, the virus neutralizing antibody titer of those samples ranged from 0.45 to 0.49 IU/ml.", [["samples", "ANATOMY", 56, 63], ["the virus neutralizing antibody titer", "TEST", 9, 46], ["those samples", "TEST", 50, 63]]], ["Sera derived from subjects which were unvaccinated or had received other vaccines such as CDV, CPV, CAV, CCV, CPIV did not show false-positive results when tested by ICTS.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["subjects", "ORGANISM", 18, 26], ["CDV", "ORGANISM", 90, 93], ["CPV", "ORGANISM", 95, 98], ["CAV", "ORGANISM", 100, 103], ["CCV", "ORGANISM", 105, 108], ["CDV", "SPECIES", 90, 93], ["CPV", "SPECIES", 95, 98], ["CAV", "SPECIES", 100, 103], ["CCV", "SPECIES", 105, 108], ["CPIV", "SPECIES", 110, 114], ["other vaccines", "TREATMENT", 67, 81], ["CDV", "TREATMENT", 90, 93], ["CPV", "TREATMENT", 95, 98], ["CAV", "ANATOMY", 100, 103]]], ["This result indicates that the ICTS is specific for sera against rabies virus.DiscussionTo date, some ELISAs or competitive ELISAs (c-ELISAs) have been developed to test serum samples and compare the results with the RFFIT or FAVN test (Bahloul et al., 2005, Cliquet et al., 2004, Muhamuda et al., 2007, Servat and Cliquet, 2006, Servat et al., 2007, Zhang et al., 2009a, Zhang et al., 2009b).", [["sera", "ANATOMY", 52, 56], ["serum samples", "ANATOMY", 170, 183], ["sera", "ORGANISM_SUBSTANCE", 52, 56], ["rabies virus", "ORGANISM", 65, 77], ["c-ELISAs", "GENE_OR_GENE_PRODUCT", 132, 140], ["serum samples", "ORGANISM_SUBSTANCE", 170, 183], ["ICTS", "DNA", 31, 35], ["rabies virus", "SPECIES", 65, 77], ["sera against rabies virus", "PROBLEM", 52, 77], ["some ELISAs", "TEST", 97, 108], ["competitive ELISAs (c-ELISAs", "PROBLEM", 112, 140], ["test serum samples", "TEST", 165, 183]]], ["However, they are still not suitable for use outside the research laboratory because of the requirement of special equipment such as a microplate reader or incubator.", [["special equipment", "TREATMENT", 107, 124], ["a microplate reader or incubator", "TREATMENT", 133, 165]]], ["A RAPId Neutralizing Antibody (RAPINA) test has been described for quantitatively measuring neutralizing antibody against rabies virus (Shiota et al., 2009).", [["rabies virus", "ORGANISM", 122, 134], ["RAPId Neutralizing Antibody", "PROTEIN", 2, 29], ["RAPINA", "PROTEIN", 31, 37], ["neutralizing antibody", "PROTEIN", 92, 113], ["rabies virus", "SPECIES", 122, 134], ["rabies virus", "SPECIES", 122, 134], ["A RAPId Neutralizing Antibody (RAPINA) test", "TEST", 0, 43], ["neutralizing antibody", "TEST", 92, 113], ["rabies virus", "PROBLEM", 122, 134], ["RAPId", "OBSERVATION_MODIFIER", 2, 7], ["Neutralizing", "OBSERVATION", 8, 20]]], ["In this method, serum is incubated with inactivated rabies virus, and then used for a RABV G detection kit based on the principle of immunochromatography as described previously (Nishizono et al., 2008).", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["rabies virus", "ORGANISM", 52, 64], ["rabies virus", "SPECIES", 52, 64], ["RABV", "SPECIES", 86, 90], ["inactivated rabies virus", "PROBLEM", 40, 64], ["a RABV G detection kit", "TREATMENT", 84, 106], ["immunochromatography", "TEST", 133, 153]]], ["In comparison with ELISAs, the RAPINA has an advantage of convenience, safety and rapidity.", [["RAPINA", "PROTEIN", 31, 37], ["ELISAs", "TEST", 19, 25]]], ["No special equipment, cultured cells, live virus, or trained operators are needed, and the results are easy to read.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["cultured cells", "CELL_LINE", 22, 36], ["live virus", "PROBLEM", 38, 48]]], ["Sera with virus neutralizing antibody titers \u2265 0.5 IU/ml could neutralize the rabies virus and would not produce a test line; however, sera with titers < 0.5 IU/ml would not inhibit the band formation on the test line when detected by the RABV G detection kit.", [["sera", "ANATOMY", 135, 139], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["rabies virus", "ORGANISM", 78, 90], ["sera", "ORGANISM_SUBSTANCE", 135, 139], ["rabies virus", "SPECIES", 78, 90], ["RABV", "SPECIES", 239, 243], ["Sera", "TEST", 0, 4], ["virus neutralizing antibody titers", "TEST", 10, 44], ["the rabies virus", "PROBLEM", 74, 90], ["a test line", "TEST", 113, 124], ["sera", "TEST", 135, 139], ["titers", "TEST", 145, 151], ["the band formation", "PROBLEM", 182, 200], ["the test line", "TEST", 204, 217]]], ["In the ICTS, 50 \u03bcl serum sample was applied to the test, two red-purple lines on the membrane indicate that the serum sample possesses a virus neutralizing antibody titer \u2265 0.5 IU/ml.", [["serum sample", "ANATOMY", 19, 31], ["membrane", "ANATOMY", 85, 93], ["serum sample", "ANATOMY", 112, 124], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["red-purple lines", "CELL_LINE", 61, 77], ["serum sample", "TEST", 19, 31], ["the test", "TEST", 47, 55], ["red-purple lines", "TREATMENT", 61, 77], ["the serum sample", "TEST", 108, 124], ["a virus neutralizing antibody titer", "TEST", 135, 170], ["purple lines", "OBSERVATION", 65, 77]]], ["If only one line appears at the control location, the serum sample is negative for rabies virus or has a virus neutralizing antibody titer < 0.5 IU/ml.", [["serum sample", "ANATOMY", 54, 66], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["rabies virus", "ORGANISM", 83, 95], ["rabies virus", "SPECIES", 83, 95], ["the serum sample", "TEST", 50, 66], ["rabies virus", "PROBLEM", 83, 95], ["a virus neutralizing antibody titer", "TEST", 103, 138], ["one line", "OBSERVATION_MODIFIER", 8, 16]]], ["Also, the stronger the test line appears, the more virus specific antibodies are present in the sample.", [["sample", "ANATOMY", 96, 102], ["virus specific antibodies", "PROTEIN", 51, 76], ["the test line", "TEST", 19, 32], ["the more virus specific antibodies", "PROBLEM", 42, 76]]], ["It should be pointed out that one disadvantage of ICTS is that the intensity of the test lines could reach to a plateau when test the serum samples with titers higher than 8.0 IU/ml.", [["serum samples", "ANATOMY", 134, 147], ["serum samples", "ORGANISM_SUBSTANCE", 134, 147], ["the test lines", "TEST", 80, 94], ["a plateau", "TEST", 110, 119], ["the serum samples", "TEST", 130, 147], ["titers", "TEST", 153, 159]]], ["This is because the amounts of colloidal gold-RABV G dispensed onto the fiberglass and Staphylococcal protein A immobilized on the membrane are constant, and even though more virus neutralizing antibodies are present in the sample, the colloidal gold-RABV G-RABV antibody complex trapped by the Staphylococcal protein A immobilized at the test line is limited, so the color cannot become stronger.", [["membrane", "ANATOMY", 131, 139], ["sample", "ANATOMY", 224, 230], ["Staphylococcal protein A", "GENE_OR_GENE_PRODUCT", 87, 111], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["Staphylococcal protein A", "GENE_OR_GENE_PRODUCT", 295, 319], ["RABV G", "PROTEIN", 46, 52], ["Staphylococcal protein A", "PROTEIN", 87, 111], ["virus neutralizing antibodies", "PROTEIN", 175, 204], ["colloidal gold-RABV G-RABV antibody complex", "PROTEIN", 236, 279], ["Staphylococcal protein A", "PROTEIN", 295, 319], ["RABV", "SPECIES", 258, 262], ["colloidal gold-RABV G", "TREATMENT", 31, 52], ["the fiberglass", "TREATMENT", 68, 82], ["Staphylococcal protein A", "PROBLEM", 87, 111], ["more virus neutralizing antibodies", "PROBLEM", 170, 204], ["the colloidal gold", "TEST", 232, 250], ["RABV G", "TEST", 251, 257], ["RABV antibody complex", "PROBLEM", 258, 279], ["the Staphylococcal protein A", "PROBLEM", 291, 319], ["the test line", "TEST", 335, 348], ["amounts", "OBSERVATION_MODIFIER", 20, 27], ["fiberglass", "OBSERVATION_MODIFIER", 72, 82], ["Staphylococcal protein", "OBSERVATION", 87, 109], ["Staphylococcal protein", "OBSERVATION", 295, 317]]], ["In this case, the serum sample should be diluted further.DiscussionIn conclusion, the ICTS is a useful method for quantitative analysis of virus neutralizing antibodies against RABV in serum and for differentiation of animals with adequate immunity from those without adequate immunity.", [["serum sample", "ANATOMY", 18, 30], ["serum", "ANATOMY", 185, 190], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["RABV", "ORGANISM", 177, 181], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["virus neutralizing antibodies", "PROTEIN", 139, 168], ["RABV", "SPECIES", 177, 181], ["the serum sample", "TEST", 14, 30], ["quantitative analysis", "TEST", 114, 135], ["virus neutralizing antibodies", "TREATMENT", 139, 168], ["RABV in serum", "TEST", 177, 190]]], ["Also, it has been adapted for testing clinical samples, and could be used as a tool for surveillance of rabies in the field and vaccination efficacy testing.", [["samples", "ANATOMY", 47, 54], ["rabies", "DISEASE", 104, 110], ["rabies", "ORGANISM", 104, 110], ["rabies", "SPECIES", 104, 110], ["testing clinical samples", "TEST", 30, 54], ["surveillance of rabies in the field", "TEST", 88, 123], ["vaccination efficacy testing", "TEST", 128, 156]]], ["Since the binding capacity with immunoglobulin of Staphylococcal protein A differs between mammalian species, this method could be modified to detect sera derived from humans or other mammals.", [["sera", "ANATOMY", 150, 154], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 32, 46], ["Staphylococcal protein A", "GENE_OR_GENE_PRODUCT", 50, 74], ["sera", "ORGANISM_SUBSTANCE", 150, 154], ["humans", "ORGANISM", 168, 174], ["immunoglobulin", "PROTEIN", 32, 46], ["Staphylococcal protein A", "PROTEIN", 50, 74], ["humans", "SPECIES", 168, 174], ["humans", "SPECIES", 168, 174], ["the binding capacity", "TEST", 6, 26], ["immunoglobulin", "TREATMENT", 32, 46], ["Staphylococcal protein", "PROBLEM", 50, 72], ["mammalian species", "PROBLEM", 91, 108], ["this method", "TREATMENT", 110, 121]]]], "0c34087bdc5220eba509f9769cbbbd1ca2a85842": [["IntroductionElectron microscopy (EM) can be used to visualize virus particles directly at high magnifications.", [["IntroductionElectron microscopy", "TEST", 0, 31], ["virus particles", "PROBLEM", 62, 77]]], ["The first investigations of the morphology and later the ultrastructure of viruses infecting humans and animals became possible, due to the invention of the EM technique in the early 1930s (Agar, 1996) , and the first micrographs showing the size and morphology of poxviruses were published in 1938 (Von Borries et al., 1938) .", [["humans", "ORGANISM", 93, 99], ["poxviruses", "ORGANISM", 265, 275], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["the first micrographs", "TEST", 208, 229], ["poxviruses", "PROBLEM", 265, 275], ["viruses", "OBSERVATION", 75, 82], ["size", "OBSERVATION_MODIFIER", 242, 246], ["morphology", "OBSERVATION_MODIFIER", 251, 261], ["poxviruses", "OBSERVATION", 265, 275]]], ["With the development of the negative contrast staining method by Brenner and Horne (1959) , viral particles could be investigated at the ultrastructural level.IntroductionDuring the following decades EM was used together with other techniques such as immunoassays, and later also with nucleic acid amplification techniques, to characterize a variety of viruses (reviewed in Biel and Gelderblom, 1999 ).", [["viral particles", "PROBLEM", 92, 107], ["immunoassays", "TEST", 251, 263], ["nucleic acid amplification techniques", "TEST", 285, 322], ["negative", "OBSERVATION_MODIFIER", 28, 36], ["contrast staining", "OBSERVATION", 37, 54], ["viral particles", "OBSERVATION", 92, 107], ["viruses", "OBSERVATION", 353, 360]]], ["This progress made it possible to establish viral classification based upon the morphology of virus particles (Tyrell and Almeida, 1967) .", [["viral classification", "PROBLEM", 44, 64]]], ["EM was used in many laboratories for routine diagnosis of human viruses causing viral gastroenteritis such as the unculturable noroviruses, and astrovirus and rotavirus (Beards, 1988; Clark and McKendrick, 2004) .IntroductionToday, EM is used routinely as a diagnostic method in cases of skin associated viral infections (Hawranek et al., 2003; Schimmer et al., 2004) and to some extent for the diagnosis of viral gastroenteritis (Frankenhauser et al., 2002; Suzuki et al., 2005) .", [["skin", "ANATOMY", 288, 292], ["viral gastroenteritis", "DISEASE", 80, 101], ["unculturable noroviruses", "DISEASE", 114, 138], ["astrovirus and rotavirus", "DISEASE", 144, 168], ["viral infections", "DISEASE", 304, 320], ["viral gastroenteritis", "DISEASE", 408, 429], ["human", "ORGANISM", 58, 63], ["skin", "ORGAN", 288, 292], ["human", "SPECIES", 58, 63], ["human viruses", "SPECIES", 58, 71], ["human viruses", "PROBLEM", 58, 71], ["viral gastroenteritis", "PROBLEM", 80, 101], ["the unculturable noroviruses", "PROBLEM", 110, 138], ["astrovirus", "PROBLEM", 144, 154], ["rotavirus", "PROBLEM", 159, 168], ["skin associated viral infections", "PROBLEM", 288, 320], ["viral gastroenteritis", "PROBLEM", 408, 429], ["viral gastroenteritis", "OBSERVATION", 80, 101], ["noroviruses", "OBSERVATION", 127, 138], ["skin", "ANATOMY", 288, 292], ["viral infections", "OBSERVATION", 304, 320], ["viral gastroenteritis", "OBSERVATION", 408, 429]]], ["EM is indispensable in situations where the etiological agent causing outbreaks, epidemics or pandemics is difficult to identify.", [["outbreaks", "PROBLEM", 70, 79], ["epidemics", "PROBLEM", 81, 90], ["pandemics", "PROBLEM", 94, 103]]], ["Recently, there have been two examples, namely the SARS pandemic in 2003 (Ksiazek et al., 2003) and the outbreak of human monkeypox in the USA in 2003, an infection not seen previously outside the African continent (Reed et al., 2004) .", [["SARS", "DISEASE", 51, 55], ["monkeypox", "DISEASE", 122, 131], ["infection", "DISEASE", 155, 164], ["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human monkeypox", "SPECIES", 116, 131], ["an infection", "PROBLEM", 152, 164], ["infection", "OBSERVATION", 155, 164]]], ["In both of these situations, EM contributed to the identification of the viral agent.", [["the viral agent", "TREATMENT", 69, 84], ["viral agent", "OBSERVATION", 73, 84]]], ["After 11th September 2001, EM has also been adopted in many countries as a rapid screening method to be used for the examination of both environmental and human samples in the case of bioterrorism (Gelderblom, 2003; Miller, 2004) .IntroductionIn the present study a strategy was developed whereby it is possible to screen by transmission EM for viruses in various types of patient samples, and then confirm and characterize the findings further at the species level by using nucleic acid amplification techniques.Experimental designFour different viruses were investigated for detection by EM and subsequent nucleic acid amplification by the method outlined in Fig. 1 .", [["samples", "ANATOMY", 161, 168], ["samples", "ANATOMY", 381, 388], ["nucleic acid", "CHEMICAL", 475, 487], ["nucleic acid", "CHEMICAL", 608, 620], ["human", "ORGANISM", 155, 160], ["patient", "ORGANISM", 373, 380], ["samples", "CANCER", 381, 388], ["human", "SPECIES", 155, 160], ["patient", "SPECIES", 373, 380], ["human", "SPECIES", 155, 160], ["a rapid screening method", "TREATMENT", 73, 97], ["the examination", "TEST", 113, 128], ["viruses", "PROBLEM", 345, 352], ["patient samples", "TEST", 373, 388], ["nucleic acid amplification techniques", "TREATMENT", 475, 512], ["Experimental designFour different viruses", "PROBLEM", 513, 554], ["subsequent nucleic acid amplification", "TREATMENT", 597, 634], ["viruses", "OBSERVATION", 547, 554]]], ["The physical and chemical properties of these viruses are shown in Table 1 .", [["viruses", "OBSERVATION", 46, 53]]], ["The initial experiments were carried out using viruses propagated in cell cultures.", [["cell cultures", "ANATOMY", 69, 82], ["cell cultures", "CELL", 69, 82], ["cell cultures", "CELL_LINE", 69, 82], ["The initial experiments", "TEST", 0, 23], ["viruses", "PROBLEM", 47, 54], ["cell cultures", "TEST", 69, 82]]], ["Thereafter, samples containing the viruses were also included in order to test the application of the method to different types of diagnostic samples.Propagation of viruses in cell culturesThe viruses propagated in cell culture for use in the experiments were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA).", [["samples", "ANATOMY", 12, 19], ["samples", "ANATOMY", 142, 149], ["cell cultures", "ANATOMY", 176, 189], ["cell culture", "ANATOMY", 215, 227], ["cell cultures", "CELL", 176, 189], ["cell culture", "CELL", 215, 227], ["cell cultures", "CELL_LINE", 176, 189], ["ATCC", "SPECIES", 312, 316], ["the viruses", "PROBLEM", 31, 42], ["the method", "TREATMENT", 98, 108], ["diagnostic samples", "TEST", 131, 149], ["Propagation of viruses", "PROBLEM", 150, 172], ["cell cultures", "TEST", 176, 189], ["The viruses", "PROBLEM", 189, 200], ["cell culture", "TEST", 215, 227], ["viruses", "OBSERVATION", 35, 42], ["viruses", "OBSERVATION", 165, 172], ["cell cultures", "OBSERVATION", 176, 189], ["viruses", "OBSERVATION", 193, 200], ["cell culture", "OBSERVATION", 215, 227]]], ["Adenoviruses (ATCC VR-5) were propagated in VERO cells using Eagles MEM culture medium with 2% fetal calf serum, influenza A viruses (ATTC VR-97) were propagated in McDarbin canine kidney cells using Eagles MEM serumfree culture medium.", [["VERO cells", "ANATOMY", 44, 54], ["fetal calf serum", "ANATOMY", 95, 111], ["kidney cells", "ANATOMY", 181, 193], ["ATTC VR-97", "CHEMICAL", 134, 144], ["ATCC VR-5", "ORGANISM", 14, 23], ["VERO cells", "CELL", 44, 54], ["Eagles MEM", "CELL", 61, 71], ["fetal calf", "ORGANISM_SUBSTANCE", 95, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["influenza A viruses", "ORGANISM", 113, 132], ["ATTC VR-97", "CELL", 134, 144], ["McDarbin canine kidney cells", "CELL", 165, 193], ["VERO cells", "CELL_LINE", 44, 54], ["McDarbin canine kidney cells", "CELL_LINE", 165, 193], ["calf", "SPECIES", 101, 105], ["canine", "SPECIES", 174, 180], ["ATCC VR-5", "SPECIES", 14, 23], ["influenza A viruses", "SPECIES", 113, 132], ["ATTC VR-97", "SPECIES", 134, 144], ["canine", "SPECIES", 174, 180], ["Adenoviruses (ATCC VR", "TEST", 0, 21], ["Eagles MEM culture medium", "TEST", 61, 86], ["fetal calf serum", "TEST", 95, 111], ["influenza A viruses", "PROBLEM", 113, 132], ["ATTC VR", "TEST", 134, 141], ["Eagles MEM", "TEST", 200, 210], ["calf serum", "ANATOMY", 101, 111], ["kidney", "ANATOMY", 181, 187]]], ["When the cells had grown to confluence in 75 cm 2 culture flasks (Nunc), viruses were added and allowed to grow until a complete cytophatic effect was attained.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["culture flasks", "TEST", 50, 64], ["viruses", "PROBLEM", 73, 80], ["a complete cytophatic effect", "PROBLEM", 118, 146], ["confluence", "OBSERVATION_MODIFIER", 28, 38], ["75 cm", "OBSERVATION_MODIFIER", 42, 47]]], ["The culture flasks with the cell cultures containing the medium were thawed and frozen twice before harvesting the viruses.", [["cell cultures", "ANATOMY", 28, 41], ["cell cultures", "CELL", 28, 41], ["cell cultures", "CELL_LINE", 28, 41], ["The culture flasks", "TEST", 0, 18], ["the cell cultures", "TEST", 24, 41], ["the viruses", "PROBLEM", 111, 122], ["viruses", "OBSERVATION", 115, 122]]], ["CMV (VR-977) were propagated in confluent human fibroblasts using Eagles MEM with 1% fetal calf serum.", [["fibroblasts", "ANATOMY", 48, 59], ["fetal calf serum", "ANATOMY", 85, 101], ["VR-977", "CHEMICAL", 5, 11], ["CMV", "ORGANISM", 0, 3], ["human", "ORGANISM", 42, 47], ["fibroblasts", "CELL", 48, 59], ["fetal calf", "ORGANISM_SUBSTANCE", 85, 95], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["confluent human fibroblasts", "CELL_TYPE", 32, 59], ["human", "SPECIES", 42, 47], ["calf", "SPECIES", 91, 95], ["CMV", "SPECIES", 0, 3], ["human", "SPECIES", 42, 47], ["CMV", "TEST", 0, 3], ["VR", "TEST", 5, 7], ["Eagles MEM", "TEST", 66, 76], ["1% fetal calf serum", "TEST", 82, 101], ["confluent", "OBSERVATION_MODIFIER", 32, 41], ["human fibroblasts", "OBSERVATION", 42, 59], ["calf", "ANATOMY", 91, 95]]], ["The supernatant was harvested and used directly as a viral preparation when a complete cytopathic effect was seen.Patient samplesThe patient samples had been submitted to the Department of Virology at the Statens Serum Institut and consisted of one eyeswab positive for adenovirus, one tracheal secretion positive for influenza A virus, one urine sample positive for CMV and one stool sample positive for norovirus.", [["supernatant", "ANATOMY", 4, 15], ["samples", "ANATOMY", 122, 129], ["samples", "ANATOMY", 141, 148], ["tracheal", "ANATOMY", 286, 294], ["urine sample", "ANATOMY", 341, 353], ["stool sample", "ANATOMY", 379, 391], ["influenza A virus", "DISEASE", 318, 335], ["norovirus", "DISEASE", 405, 414], ["patient", "ORGANISM", 133, 140], ["adenovirus", "ORGANISM", 270, 280], ["tracheal", "ORGAN", 286, 294], ["influenza A virus", "ORGANISM", 318, 335], ["urine", "ORGANISM_SUBSTANCE", 341, 346], ["CMV", "ORGANISM", 367, 370], ["Patient", "SPECIES", 114, 121], ["patient", "SPECIES", 133, 140], ["influenza A virus", "SPECIES", 318, 335], ["adenovirus", "SPECIES", 270, 280], ["influenza A virus", "SPECIES", 318, 335], ["CMV", "SPECIES", 367, 370], ["a viral preparation", "TREATMENT", 51, 70], ["a complete cytopathic effect", "PROBLEM", 76, 104], ["Patient samples", "TEST", 114, 129], ["one eyeswab", "TEST", 245, 256], ["adenovirus", "PROBLEM", 270, 280], ["one tracheal secretion", "TEST", 282, 304], ["influenza A virus", "PROBLEM", 318, 335], ["one urine sample", "TEST", 337, 353], ["CMV", "PROBLEM", 367, 370], ["one stool sample", "TEST", 375, 391], ["norovirus", "PROBLEM", 405, 414], ["harvested", "OBSERVATION", 20, 29], ["tracheal", "ANATOMY", 286, 294], ["norovirus", "OBSERVATION", 405, 414]]], ["The real time PCR values were obtained from the routine diagnostic test.", [["The real time PCR values", "TEST", 0, 24], ["the routine diagnostic test", "TEST", 44, 71]]], ["All patient samples had low cycle threshold (Ct) values, indicating that the samples had high viral titres.", [["samples", "ANATOMY", 12, 19], ["samples", "ANATOMY", 77, 84], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["All patient samples", "TEST", 0, 19], ["low cycle threshold", "PROBLEM", 24, 43], ["Ct) values", "TEST", 45, 55], ["the samples", "TEST", 73, 84], ["high viral titres", "PROBLEM", 89, 106], ["viral titres", "OBSERVATION", 94, 106]]], ["The Ct value is the value that is obtained, when the fluorescent signal from the PCR product exceeds that of the background.Fixation and preparation of viral samples for EMBefore EM, all samples were inactivated with paraformaldehyde (PFA).", [["samples", "ANATOMY", 158, 165], ["samples", "ANATOMY", 187, 194], ["paraformaldehyde", "CHEMICAL", 217, 233], ["PFA", "CHEMICAL", 235, 238], ["paraformaldehyde", "SIMPLE_CHEMICAL", 217, 233], ["PFA", "SIMPLE_CHEMICAL", 235, 238], ["The Ct value", "TEST", 0, 12], ["the fluorescent signal", "TEST", 49, 71], ["the PCR product", "TEST", 77, 92], ["Fixation", "TREATMENT", 124, 132], ["viral samples", "TEST", 152, 165], ["all samples", "TEST", 183, 194], ["paraformaldehyde (PFA", "TREATMENT", 217, 238]]], ["Frozen 4% PFA in phosphate-buffered saline (pH 7.4) was heated to 65 \u2022 C in closed vials.", [["phosphate", "CHEMICAL", 17, 26], ["PFA", "CHEMICAL", 10, 13], ["phosphate", "CHEMICAL", 17, 26], ["PFA", "SIMPLE_CHEMICAL", 10, 13], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 17, 42], ["Frozen", "TEST", 0, 6], ["phosphate-buffered saline", "TREATMENT", 17, 42], ["pH", "TEST", 44, 46]]], ["When the PFA was dissolved completely, it was cooled on ice for 2 min and added to the samples at a final concentration of 2% in a total sample volume of 180 l.", [["samples", "ANATOMY", 87, 94], ["sample", "ANATOMY", 137, 143], ["PFA", "CHEMICAL", 9, 12], ["PFA", "SIMPLE_CHEMICAL", 9, 12], ["a total sample volume", "TREATMENT", 129, 150]]], ["The samples were transferred to airfuge vials and centrifuged at 90.000 rpm onto formvar coated carbon reinforced 400 mesh copper grids (Veco-grid's, AxLab) for 30 min in an airfuge using a A-100/30 rotor (Beckman Coulter).", [["samples", "ANATOMY", 4, 11], ["copper", "CHEMICAL", 123, 129], ["carbon", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 123, 129], ["The samples", "TEST", 0, 11], ["formvar coated carbon reinforced", "TREATMENT", 81, 113], ["mesh copper grids", "TREATMENT", 118, 135], ["Veco", "TEST", 137, 141], ["a A-100/30 rotor (Beckman Coulter", "TREATMENT", 188, 221]]], ["The grids were stained negatively with a 1.5% (pH 6.8) potassium phosphotungstic acid (PTA) solution for 30 s and allowed to dry in a fume-hood.", [["potassium phosphotungstic acid", "CHEMICAL", 55, 85], ["PTA", "CHEMICAL", 87, 90], ["potassium phosphotungstic acid", "CHEMICAL", 55, 85], ["PTA", "CHEMICAL", 87, 90], ["potassium phosphotungstic acid", "SIMPLE_CHEMICAL", 55, 85], ["PTA", "SIMPLE_CHEMICAL", 87, 90], ["The grids", "TEST", 0, 9], ["pH", "TEST", 47, 49], ["potassium phosphotungstic acid", "TEST", 55, 85]]], ["The EM examination was conducted with a transmission electron microscope (Morgagni 268D, FEI Company) for an average of 30 min/specimen.", [["specimen", "ANATOMY", 127, 135], ["The EM examination", "TEST", 0, 18], ["a transmission electron microscope", "TEST", 38, 72]]], ["Between 8 and 10 \"windows\" of the 400 mesh grid were scanned and photographs were taken using a Megaview III digital camera (Soft Imaging System).Elution of viral nucleic acids from the EM gridsViral DNA or RNA was eluted from the viral particles adhering to the copper grids ( Fig. 1) , by placing the grid into a vial and adding 300 l of lysis buffer (Roche).", [["nucleic acids", "CHEMICAL", 163, 176], ["copper", "CHEMICAL", 263, 269], ["copper", "CHEMICAL", 263, 269], ["Viral", "ORGANISM", 194, 199], ["DNA", "CELLULAR_COMPONENT", 200, 203], ["the 400 mesh grid", "TREATMENT", 30, 47], ["photographs", "TEST", 65, 76], ["a Megaview III digital camera", "TREATMENT", 94, 123], ["viral nucleic acids", "PROBLEM", 157, 176], ["Viral DNA", "PROBLEM", 194, 203], ["RNA", "PROBLEM", 207, 210], ["the viral particles", "PROBLEM", 227, 246], ["the copper grids", "TREATMENT", 259, 275], ["lysis buffer", "TREATMENT", 340, 352], ["viral nucleic acids", "OBSERVATION", 157, 176], ["viral particles", "OBSERVATION", 231, 246]]], ["After 10 min, 200 l of sterile water was added, and the grid was vortex'ed for 1 min.", [["sterile water", "TREATMENT", 23, 36]]], ["The grid was then removed from the vial and the nucleic acids were purified for amplification by extraction on a MagNapure instrument using a total nucleic acids extraction kit (Roche Diagnostics).", [["nucleic acids", "CHEMICAL", 48, 61], ["nucleic acids", "CHEMICAL", 148, 161], ["the nucleic acids", "TEST", 44, 61], ["a MagNapure instrument", "TREATMENT", 111, 133], ["a total nucleic acids extraction", "TREATMENT", 140, 172]]], ["The nucleic acids were stored in elution buffer at \u221220 \u2022 C until use.Real-time PCR and RT-PCRAdenovirus nucleic acid was detected with fluorescent probes using a Lightcycler (Roche) instrument as described by Heim et al. (2003) with minor modifications.", [["nucleic acids", "CHEMICAL", 4, 17], ["nucleic acid", "CHEMICAL", 104, 116], ["nucleic acids", "SIMPLE_CHEMICAL", 4, 17], ["The nucleic acids", "TREATMENT", 0, 17], ["Real-time PCR", "TEST", 69, 82], ["RT-PCRAdenovirus nucleic acid", "TEST", 87, 116], ["a Lightcycler (Roche) instrument", "TREATMENT", 160, 192], ["minor modifications", "TREATMENT", 233, 252]]], ["Influenza A virus and CMV nucleic acids were detected with fluorescent probes using a MX3000 detection device (Stratagene) with real-time RT-PCR (influenza A) or PCR (CMV) assays for each virus with minor modifications as compared to published real-time assays (Spackman et al., 2002; Boechk et al., 2004) .", [["nucleic acids", "CHEMICAL", 26, 39], ["Influenza A virus", "ORGANISM", 0, 17], ["CMV", "ORGANISM", 22, 25], ["CMV", "ORGANISM", 167, 170], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["CMV", "SPECIES", 22, 25], ["CMV", "SPECIES", 167, 170], ["Influenza A virus", "PROBLEM", 0, 17], ["CMV nucleic acids", "TEST", 22, 39], ["fluorescent probes", "TEST", 59, 77], ["a MX3000 detection device", "TREATMENT", 84, 109], ["influenza", "PROBLEM", 146, 155], ["PCR (CMV) assays", "TEST", 162, 178], ["each virus", "PROBLEM", 183, 193], ["minor modifications", "PROBLEM", 199, 218]]], ["Norovirus RNA was RT-PCR amplified and detected on an ethidium bromide stained 2% agarose gel as described by Vinje et al. (1997) .Testing for viral genomes derived from viruses adhered to grids for subsequent nucleic acid amplificationInitially, it was determined whether it was possible to elute virus constituents from negatively stained grids and then detect the viral nucleic acids by nucleic acid amplification.", [["ethidium bromide", "CHEMICAL", 54, 70], ["nucleic acid", "CHEMICAL", 210, 222], ["nucleic acids", "CHEMICAL", 373, 386], ["nucleic acid", "CHEMICAL", 390, 402], ["ethidium bromide", "CHEMICAL", 54, 70], ["Norovirus", "ORGANISM", 0, 9], ["ethidium bromide", "SIMPLE_CHEMICAL", 54, 70], ["agarose", "SIMPLE_CHEMICAL", 82, 89], ["Norovirus RNA", "RNA", 0, 13], ["viral genomes", "DNA", 143, 156], ["Norovirus RNA", "PROBLEM", 0, 13], ["RT-PCR", "TEST", 18, 24], ["an ethidium bromide stained 2% agarose gel", "TREATMENT", 51, 93], ["Testing", "TEST", 131, 138], ["viral genomes", "PROBLEM", 143, 156], ["viruses", "PROBLEM", 170, 177], ["subsequent nucleic acid amplification", "TREATMENT", 199, 236], ["elute virus constituents", "PROBLEM", 292, 316], ["negatively stained grids", "PROBLEM", 322, 346], ["the viral nucleic acids", "PROBLEM", 363, 386], ["nucleic acid amplification", "TREATMENT", 390, 416]]], ["One sample each of cell propagated adenovirus and influenza A virus, respectively, was extracted directly using MagnaPure extraction and then subjected to nucleic acid amplification (unprocessed sample).", [["sample", "ANATOMY", 4, 10], ["cell", "ANATOMY", 19, 23], ["sample", "ANATOMY", 195, 201], ["nucleic acid", "CHEMICAL", 155, 167], ["cell", "CELL", 19, 23], ["adenovirus", "ORGANISM", 35, 45], ["influenza A virus", "ORGANISM", 50, 67], ["MagnaPure", "SIMPLE_CHEMICAL", 112, 121], ["influenza A virus", "SPECIES", 50, 67], ["influenza A virus", "SPECIES", 50, 67], ["cell propagated adenovirus", "PROBLEM", 19, 45], ["influenza A virus", "PROBLEM", 50, 67], ["MagnaPure extraction", "TREATMENT", 112, 132], ["nucleic acid amplification", "TREATMENT", 155, 181], ["cell propagated adenovirus", "OBSERVATION", 19, 45]]], ["In addition, two samples (1x + EM) were subjected to EM examination prior to MagnaPure extraction and nucleic acid amplification as shown in Fig. 1 .", [["samples", "ANATOMY", 17, 24], ["nucleic acid", "CHEMICAL", 102, 114], ["two samples", "TEST", 13, 24], ["EM examination", "TEST", 53, 67], ["MagnaPure extraction", "TREATMENT", 77, 97], ["nucleic acid amplification", "TREATMENT", 102, 128]]], ["A quantitative real-time assay was used for adenovirus ( Fig. 2A) , using the standard curve to calculate the average loss of viral copies per ml for the processed (1x + EM) sample relative to the unprocessed sample, according to the formula (Ct intercept \u2212 Ct sample /slope) \u00d7 inv. log.", [["sample", "ANATOMY", 209, 215], ["adenovirus", "ORGANISM", 44, 54], ["adenovirus", "SPECIES", 44, 54], ["A quantitative real-time assay", "TEST", 0, 30], ["adenovirus", "PROBLEM", 44, 54], ["Ct intercept", "TEST", 243, 255], ["Ct sample", "TEST", 258, 267]]], ["The difference was estimated to be a 38-fold loss of sensitivity Fig. 1 , except that (+EM) samples were exposed to the EM beam, while (\u2212EM) samples were unexposed.", [["samples", "ANATOMY", 92, 99], ["samples", "ANATOMY", 141, 148], ["a 38-fold loss of sensitivity Fig.", "PROBLEM", 35, 69], ["38-fold", "OBSERVATION_MODIFIER", 37, 44]]], ["The unprocessed samples were untreated and extracted directly using MagnaPure extraction.", [["samples", "ANATOMY", 16, 23], ["MagnaPure", "SIMPLE_CHEMICAL", 68, 77], ["The unprocessed samples", "TEST", 0, 23], ["MagnaPure extraction", "TREATMENT", 68, 88]]], ["The standard curve for the adenovirus quantitative real-time PCR is also shown on the figure. i.e. from 2.3 \u00d7 10 8 copies/ml (Ct = 17.49) to 6 \u00d7 10 6 copies/ml (Ct = 23.20).", [["adenovirus", "ORGANISM", 27, 37], ["adenovirus", "SPECIES", 27, 37], ["the adenovirus quantitative real-time PCR", "TEST", 23, 64], ["Ct", "TEST", 126, 128], ["Ct", "TEST", 161, 163]]], ["From the Ct value of the highest dilution (100x + EM, Ct = 32.34) it could then be calculated, that 6.84 \u00d7 10 5 copies/ml of adenovirus could be detected by EM and this corresponded to 6.84 \u00d7 10 5 /38 = 1.8 \u00d7 10 4 copies/ml as detected by PCR.", [["adenovirus", "ORGANISM", 125, 135], ["adenovirus", "SPECIES", 125, 135], ["the Ct value", "TEST", 5, 17], ["the highest dilution", "TEST", 21, 41], ["Ct", "TEST", 54, 56], ["adenovirus", "PROBLEM", 125, 135], ["copies/ml", "TEST", 214, 223], ["PCR", "TEST", 239, 242]]], ["Although influenza A virus (Fig. 2B ) was detected using a non-quantitative assay, the loss in PCR cycles (Ct sample \u2212 Ct unprocessed sample = 17.79 \u2212 12.15) could be measured to be 5.64 which was in good agreement with the result estimated with the adenovirus assay.Testing of differences in viral nucleic acid concentration between grids with viral preparations with and without EMNext, the difference in the amount of viral copies between grids that had been processed by the method outlined in Fig. 1 and grids that had also been processed by the method except for exposure to the EM beam was investigated [(+EM) and (\u2212EM)].", [["nucleic acid", "CHEMICAL", 299, 311], ["influenza A virus", "ORGANISM", 9, 26], ["Fig. 2B", "ORGANISM", 28, 35], ["adenovirus", "ORGANISM", 250, 260], ["influenza A virus", "SPECIES", 9, 26], ["influenza A virus", "SPECIES", 9, 26], ["adenovirus", "SPECIES", 250, 260], ["influenza A virus", "PROBLEM", 9, 26], ["a non-quantitative assay", "TEST", 57, 81], ["the loss in PCR cycles", "PROBLEM", 83, 105], ["Ct sample", "TEST", 107, 116], ["Ct unprocessed sample", "TEST", 119, 140], ["the adenovirus assay", "TEST", 246, 266], ["viral nucleic acid concentration", "TREATMENT", 293, 325], ["viral preparations", "TREATMENT", 345, 363], ["EMNext", "TREATMENT", 381, 387], ["viral copies between grids", "PROBLEM", 421, 447], ["viral copies", "OBSERVATION", 421, 433]]], ["As depicted in Fig. 2 , over a 100-fold dilution range, viruses were detected as particles by EM and also as viral genomes by nucleic acids amplification in all samples tested and no differences were detected between any of the samples for each dilution.Amplification of viral nucleic acids from patient samples after elution from gridsFinally, the same procedure was examined with stored patient samples that had been diagnosed previously as adenovirus, influenza A, CMV or norovirus positive in the PCR diagnostic laboratory.", [["samples", "ANATOMY", 161, 168], ["samples", "ANATOMY", 228, 235], ["samples", "ANATOMY", 304, 311], ["samples", "ANATOMY", 397, 404], ["nucleic acids", "CHEMICAL", 126, 139], ["nucleic acids", "CHEMICAL", 277, 290], ["influenza A, CMV or norovirus positive", "DISEASE", 455, 493], ["nucleic acids", "SIMPLE_CHEMICAL", 126, 139], ["patient", "ORGANISM", 296, 303], ["patient", "ORGANISM", 389, 396], ["adenovirus", "ORGANISM", 443, 453], ["influenza A", "ORGANISM", 455, 466], ["CMV", "ORGANISM", 468, 471], ["norovirus", "ORGANISM", 475, 484], ["viral genomes", "DNA", 109, 122], ["patient", "SPECIES", 296, 303], ["patient", "SPECIES", 389, 396], ["CMV", "SPECIES", 468, 471], ["norovirus", "SPECIES", 475, 484], ["viruses", "PROBLEM", 56, 63], ["viral genomes", "PROBLEM", 109, 122], ["nucleic acids amplification", "TEST", 126, 153], ["all samples", "TEST", 157, 168], ["viral nucleic acids", "PROBLEM", 271, 290], ["the same procedure", "TREATMENT", 345, 363], ["adenovirus", "PROBLEM", 443, 453], ["influenza", "PROBLEM", 455, 464], ["CMV", "PROBLEM", 468, 471], ["norovirus", "PROBLEM", 475, 484], ["Fig", "OBSERVATION", 15, 18], ["viral nucleic acids", "OBSERVATION", 271, 290]]], ["For this purpose patient samples of different origin with a known high viral load were chosen, allowing detection by EM.", [["samples", "ANATOMY", 25, 32], ["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["a known high viral load", "PROBLEM", 58, 81], ["high", "OBSERVATION_MODIFIER", 66, 70], ["viral load", "OBSERVATION", 71, 81]]], ["The patient samples that were used are listed in Table 2 .AdenovirusThe results are shown in Fig. 3A .", [["samples", "ANATOMY", 12, 19], ["patient", "ORGANISM", 4, 11], ["Adenovirus", "ORGANISM", 58, 68], ["patient", "SPECIES", 4, 11], ["Adenovirus", "SPECIES", 58, 68], ["Adenovirus", "PROBLEM", 58, 68]]], ["Adenovirus particles were detected in the sample by EM and subsequently, after elution, also the viral genomes by nucleic acid amplification.", [["sample", "ANATOMY", 42, 48], ["nucleic acid", "CHEMICAL", 114, 126], ["Adenovirus", "ORGANISM", 0, 10], ["viral genomes", "DNA", 97, 110], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus particles", "PROBLEM", 0, 20], ["the viral genomes", "TREATMENT", 93, 110], ["nucleic acid amplification", "TREATMENT", 114, 140], ["viral genomes", "OBSERVATION", 97, 110]]], ["As a positive control, a standard of 10 5 copies/ml was included in the RT-PCR assay.", [["the RT-PCR assay", "TEST", 68, 84]]], ["The negative control is not shown in the figure, as this curve is not available with the lightcycler assay due to the lack of a reference dye.Influenza A virusThe results are shown in Fig. 3B .", [["Influenza A virus", "DISEASE", 142, 159], ["Influenza A virus", "ORGANISM", 142, 159], ["Influenza A virus", "SPECIES", 142, 159], ["Influenza A virus", "SPECIES", 142, 159], ["this curve", "TEST", 52, 62], ["the lightcycler assay", "TEST", 85, 106], ["Influenza A virus", "PROBLEM", 142, 159], ["negative", "OBSERVATION", 4, 12]]], ["A positive control used in the routine diagnostic assay was included in the real-time RT-PCR together with a non-template negative control.CytomegalovirusIn Fig. 4A , an EM picture of CMV particles derived from a cell culture sample is included for comparison to the EM picture of the patient sample, since only solitary CMV particles were found in the patient sample.", [["cell culture sample", "ANATOMY", 213, 232], ["CMV", "ORGANISM", 184, 187], ["cell", "CELL", 213, 217], ["patient", "ORGANISM", 285, 292], ["CMV", "ORGANISM", 321, 324], ["patient", "ORGANISM", 353, 360], ["patient", "SPECIES", 285, 292], ["patient", "SPECIES", 353, 360], ["CMV", "SPECIES", 184, 187], ["CMV", "SPECIES", 321, 324], ["the routine diagnostic assay", "TEST", 27, 55], ["a non-template negative control", "TREATMENT", 107, 138], ["an EM picture", "TEST", 167, 180], ["CMV particles", "PROBLEM", 184, 197], ["a cell culture sample", "TEST", 211, 232], ["solitary CMV particles", "PROBLEM", 312, 334], ["CMV particles", "OBSERVATION", 184, 197], ["solitary", "OBSERVATION_MODIFIER", 312, 320], ["CMV particles", "OBSERVATION", 321, 334]]], ["The real-time PCR was quantitative, and the positive control was a sample containing 3.5 \u00d7 10 5 copies/ml which was included together with a nontemplate negative control.NorovirusThe results are shown in Fig. 4B .", [["sample", "ANATOMY", 67, 73], ["Norovirus", "DISEASE", 170, 179], ["4B", "GENE_OR_GENE_PRODUCT", 209, 211], ["The real-time PCR", "TEST", 0, 17], ["a nontemplate negative control", "TREATMENT", 139, 169], ["Norovirus", "PROBLEM", 170, 179]]], ["Small rounded 35 nm particles were visualised in the EM sample.", [["sample", "ANATOMY", 56, 62], ["Small rounded 35 nm particles", "PROBLEM", 0, 29], ["the EM sample", "TEST", 49, 62], ["rounded", "OBSERVATION_MODIFIER", 6, 13], ["35 nm", "OBSERVATION_MODIFIER", 14, 19], ["particles", "OBSERVATION_MODIFIER", 20, 29]]], ["In the RT-PCR assay which was non-quantitative, a positive patient sample and a non-template sample were included as controls.DiscussionIn the present investigation, viruses differing in respect of both physical and chemical properties were diagnosed by EM and, after elution from the EM grids diagnosed at the species level by nucleic acid amplification.DiscussionThere was a 38-fold decrease in viral copies, when untreated cell culture derived viral samples were measured by real-time PCR as compared to samples that had been subjected to EM examination.", [["non-template sample", "ANATOMY", 80, 99], ["cell", "ANATOMY", 426, 430], ["samples", "ANATOMY", 453, 460], ["samples", "ANATOMY", 507, 514], ["nucleic acid", "CHEMICAL", 328, 340], ["patient", "ORGANISM", 59, 66], ["cell", "CELL", 426, 430], ["patient", "SPECIES", 59, 66], ["the RT-PCR assay", "TEST", 3, 19], ["a positive patient sample", "PROBLEM", 48, 73], ["a non-template sample", "TEST", 78, 99], ["viruses", "PROBLEM", 166, 173], ["nucleic acid amplification", "TREATMENT", 328, 354], ["a 38-fold decrease in viral copies", "PROBLEM", 375, 409], ["untreated cell culture", "TEST", 416, 438], ["viral samples", "TEST", 447, 460], ["EM examination", "TEST", 542, 556], ["viral copies", "OBSERVATION", 397, 409]]], ["There were no major differences in the number of viral copies that could be detected on grids which had been exposed to the EM beam and the grids that had not been exposed to the EM beam over a 100-fold dilution range, indicating that this step does not contribute to the 38-fold decrease in viral copies.", [["major differences", "PROBLEM", 14, 31], ["viral copies", "PROBLEM", 49, 61], ["the 38-fold decrease in viral copies", "PROBLEM", 268, 304], ["no", "UNCERTAINTY", 11, 13], ["major", "OBSERVATION_MODIFIER", 14, 19], ["differences", "OBSERVATION_MODIFIER", 20, 31], ["viral copies", "OBSERVATION", 292, 304]]], ["The decrease in viral copies could be due to a percentage of the viruses remaining in the supernatant after centrifugation onto the grids or that part of the viruses were not visible by EM after centrifugation onto the grid, due to the viruses adhering to the copper mesh or due to some degradation of nucleic acids during the sample preparation.", [["supernatant", "ANATOMY", 90, 101], ["sample", "ANATOMY", 327, 333], ["copper", "CHEMICAL", 260, 266], ["nucleic acids", "CHEMICAL", 302, 315], ["copper", "CHEMICAL", 260, 266], ["copper mesh", "SIMPLE_CHEMICAL", 260, 271], ["nucleic acids", "SIMPLE_CHEMICAL", 302, 315], ["The decrease in viral copies", "PROBLEM", 0, 28], ["the viruses", "PROBLEM", 61, 72], ["the viruses", "PROBLEM", 154, 165], ["the viruses", "PROBLEM", 232, 243], ["the copper mesh", "TREATMENT", 256, 271], ["nucleic acids", "TREATMENT", 302, 315], ["the sample preparation", "TREATMENT", 323, 345], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["viral copies", "OBSERVATION", 16, 28], ["could be due to", "UNCERTAINTY", 29, 44], ["viruses", "OBSERVATION", 65, 72], ["viruses", "OBSERVATION", 158, 165], ["viruses", "OBSERVATION", 236, 243], ["mesh", "OBSERVATION", 267, 271], ["nucleic acids", "OBSERVATION", 302, 315]]], ["As estimated for adenovirus it could, however, be compensated for by the higher sensitivity of the PCR technique and therefore has no negative impact on the results.DiscussionIn a recent study by Biel et al. (2004) the detection of polyomavirus in urine samples from bone marrow transplant patients was done in parallel with EM and PCR.", [["urine samples", "ANATOMY", 248, 261], ["bone marrow", "ANATOMY", 267, 278], ["adenovirus", "ORGANISM", 17, 27], ["polyomavirus", "ORGANISM", 232, 244], ["urine samples", "ORGANISM_SUBSTANCE", 248, 261], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 267, 278], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["adenovirus", "SPECIES", 17, 27], ["adenovirus", "PROBLEM", 17, 27], ["the PCR technique", "TEST", 95, 112], ["a recent study", "TEST", 178, 192], ["polyomavirus", "PROBLEM", 232, 244], ["urine samples", "TEST", 248, 261], ["bone marrow transplant", "TREATMENT", 267, 289], ["PCR", "TEST", 332, 335], ["polyomavirus", "OBSERVATION", 232, 244], ["bone", "ANATOMY", 267, 271]]], ["Within a range of probabilities of detection by EM it was found that there was a 50% probability of identifying viruses in samples containing 10 6 genome equivalents/ml, and the lower limit for EM detection was estimated to be >10 3 genome equivalents/ml.", [["samples", "ANATOMY", 123, 130], ["viruses in samples", "PROBLEM", 112, 130], ["EM detection", "TEST", 194, 206], ["viruses", "OBSERVATION", 112, 119], ["lower limit", "OBSERVATION_MODIFIER", 178, 189]]], ["Our results showed, that adenovirus particles could be detected in cell culture corresponding to 6.84 \u00d7 10 5 genome equivalents/ml.", [["cell culture", "ANATOMY", 67, 79], ["adenovirus", "ORGANISM", 25, 35], ["cell culture", "CELL", 67, 79], ["adenovirus", "SPECIES", 25, 35], ["adenovirus particles", "PROBLEM", 25, 45], ["cell culture", "TEST", 67, 79]]], ["The lower limit of detection by EM when using the approach described in the present study awaits further investigation.DiscussionThe morphology of viruses belonging to the same family is unique for each particular family.", [["the approach", "TREATMENT", 46, 58], ["the present study", "TEST", 72, 89], ["further investigation", "TEST", 97, 118], ["lower limit", "OBSERVATION_MODIFIER", 4, 15]]], ["For instance, coronaviruses with their club-like peplomers, or influenza viruses with their cogwheel-like appearance are recognised easily.DiscussionThe EM technique has been used occasionally in parallel with other virological methods to identify the causative viral agent in patients during outbreaks of zoonotic origin and during seasonal and out-of-season epidemics and pandemics.", [["influenza viruses", "DISEASE", 63, 80], ["coronaviruses", "ORGANISM", 14, 27], ["influenza viruses", "ORGANISM", 63, 80], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["coronaviruses", "PROBLEM", 14, 27], ["their club-like peplomers", "PROBLEM", 33, 58], ["influenza viruses", "PROBLEM", 63, 80], ["pandemics", "PROBLEM", 374, 383], ["influenza viruses", "OBSERVATION", 63, 80]]], ["For instance, in one case report, reovirus-like particles were found by EM in rhesus monkey kidney cells inoculated with cerebrospinal fluid from a young patient, and further investigations confirmed the diagnosis reovirus serotype 2 (Hermann et al., 2004) .", [["kidney cells", "ANATOMY", 92, 104], ["cerebrospinal fluid", "ANATOMY", 121, 140], ["reovirus", "ORGANISM", 34, 42], ["rhesus", "ORGANISM", 78, 84], ["monkey", "ORGANISM", 85, 91], ["kidney cells", "CELL", 92, 104], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 121, 140], ["patient", "ORGANISM", 154, 161], ["reovirus", "ORGANISM", 214, 222], ["rhesus monkey kidney cells", "CELL_TYPE", 78, 104], ["rhesus monkey", "SPECIES", 78, 91], ["patient", "SPECIES", 154, 161], ["rhesus monkey", "SPECIES", 78, 91], ["reovirus-like particles", "PROBLEM", 34, 57], ["cerebrospinal fluid", "TEST", 121, 140], ["further investigations", "TEST", 167, 189], ["cerebrospinal fluid", "OBSERVATION", 121, 140]]], ["The same approach was used to diagnose Chandipura virus causing an outbreak of acute encephalitis with a high fatality rate in children from India (Rao et al., 2004) .", [["Chandipura virus", "DISEASE", 39, 55], ["encephalitis", "DISEASE", 85, 97], ["Chandipura virus", "ORGANISM", 39, 55], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["Chandipura virus", "SPECIES", 39, 55], ["Chandipura virus", "PROBLEM", 39, 55], ["acute encephalitis", "PROBLEM", 79, 97], ["outbreak", "OBSERVATION_MODIFIER", 67, 75], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["encephalitis", "OBSERVATION", 85, 97]]], ["The etiological agent involved in a zoonotic outbreak in a rural area of Brasil causing cowpox-like symptoms in a dairy herd, and an associated human infection, was resolved partly with the aid of EM and was found to be a vaccinia-like virus, which was named Aracatuba virus (Trinidade et al., 2003) .", [["cowpox-like symptoms", "DISEASE", 88, 108], ["human infection", "DISEASE", 144, 159], ["cowpox", "ORGANISM", 88, 94], ["human", "ORGANISM", 144, 149], ["vaccinia-like virus", "ORGANISM", 222, 241], ["Aracatuba virus", "ORGANISM", 259, 274], ["human", "SPECIES", 144, 149], ["Aracatuba virus", "SPECIES", 259, 274], ["human", "SPECIES", 144, 149], ["Aracatuba virus", "SPECIES", 259, 274], ["cowpox-like symptoms", "PROBLEM", 88, 108], ["an associated human infection", "PROBLEM", 130, 159], ["a vaccinia-like virus", "PROBLEM", 220, 241], ["zoonotic", "OBSERVATION_MODIFIER", 36, 44], ["cowpox", "OBSERVATION", 88, 94], ["infection", "OBSERVATION", 150, 159], ["vaccinia", "OBSERVATION", 222, 230]]], ["The peak of rotavirus infections in children during the winter in Japan was found to have changed to early spring by confirming the rotavirus diagnosis in parallel with EM and the latex agglutination method (Suzuki et al., 2005) .", [["rotavirus infections", "DISEASE", 12, 32], ["rotavirus", "ORGANISM", 12, 21], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["rotavirus", "SPECIES", 12, 21], ["rotavirus", "SPECIES", 132, 141], ["rotavirus infections", "PROBLEM", 12, 32], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["rotavirus", "OBSERVATION_MODIFIER", 12, 21], ["infections", "OBSERVATION", 22, 32]]], ["In recent years, noroviruses have become a major problem in hospitals worldwide, causing outbreaks of viral gastroenteritis (reviewed by Clark and McKendrick, 2004) .", [["noroviruses", "DISEASE", 17, 28], ["viral gastroenteritis", "DISEASE", 102, 123], ["noroviruses", "ORGANISM", 17, 28], ["noroviruses", "PROBLEM", 17, 28], ["viral gastroenteritis", "PROBLEM", 102, 123], ["noroviruses", "OBSERVATION", 17, 28], ["viral gastroenteritis", "OBSERVATION", 102, 123]]], ["The high diversity of this group of viruses leads sometimes to the failure of detection by conventional routine diagnostic RT-PCR assays.", [["conventional routine diagnostic RT-PCR assays", "TEST", 91, 136], ["high", "OBSERVATION_MODIFIER", 4, 8], ["diversity", "OBSERVATION_MODIFIER", 9, 18]]], ["Finally, the recent pandemic caused by SARS was also resolved partly by EM (Ksiazek et al., 2003) .DiscussionA morphological diagnosis can be made by EM, including enrichment (see Gentile and Gelderblom, 2005) , within 1 h after receiving a specimen and will provide a diagnosis.", [["specimen", "ANATOMY", 241, 249], ["SARS", "DISEASE", 39, 43], ["SARS", "PROBLEM", 39, 43]]], ["In addition, the \"open view\" of EM allows for the simultaneous detection of more than one agent in multiply infections, which is also sometimes the case in patients with gastroenteritis (Hazelton and Gelderblom, 2003) .DiscussionIn summary, a method was developed whereby it is possible to diagnose viruses in cell culture and in patient samples by EM pre-diagnosis and subsequently, by using the same sample material eluted from a grid, establish the viral diagnosis at the strain level using nucleic acid amplification.", [["cell culture", "ANATOMY", 310, 322], ["samples", "ANATOMY", 338, 345], ["infections", "DISEASE", 108, 118], ["gastroenteritis", "DISEASE", 170, 185], ["nucleic acid", "CHEMICAL", 494, 506], ["patients", "ORGANISM", 156, 164], ["cell culture", "CELL", 310, 322], ["patient", "ORGANISM", 330, 337], ["patients", "SPECIES", 156, 164], ["patient", "SPECIES", 330, 337], ["the simultaneous detection", "TEST", 46, 72], ["multiply infections", "PROBLEM", 99, 118], ["gastroenteritis", "PROBLEM", 170, 185], ["cell culture", "TEST", 310, 322], ["nucleic acid amplification", "TREATMENT", 494, 520], ["infections", "OBSERVATION", 108, 118], ["gastroenteritis", "OBSERVATION", 170, 185]]], ["The method is versatile and can be used for different types of sample material and all kinds of agents.", [["sample material", "TREATMENT", 63, 78], ["agents", "TREATMENT", 96, 102]]]], "PMC7413058": [["IntroductionThe COVID-19 pandemic continues to ravage India and the world with its high transmissibility and varying degree of virulence.", [["The COVID", "TREATMENT", 12, 21], ["its high transmissibility", "PROBLEM", 79, 104], ["virulence", "PROBLEM", 127, 136], ["varying", "OBSERVATION_MODIFIER", 109, 116], ["degree", "OBSERVATION_MODIFIER", 117, 123], ["virulence", "OBSERVATION", 127, 136]]], ["As the causative agent SARS CoV2 is a novel coronavirus, prior infection with other endemic coronaviruses does not confer any protection.", [["SARS", "DISEASE", 23, 27], ["coronavirus", "DISEASE", 44, 55], ["infection", "DISEASE", 63, 72], ["SARS CoV2", "ORGANISM", 23, 32], ["coronavirus", "ORGANISM", 44, 55], ["coronaviruses", "ORGANISM", 92, 105], ["SARS CoV2", "SPECIES", 23, 32], ["a novel coronavirus", "PROBLEM", 36, 55], ["prior infection", "PROBLEM", 57, 72], ["other endemic coronaviruses", "PROBLEM", 78, 105], ["infection", "OBSERVATION", 63, 72]]], ["Due to immune naivety of the population and ease of international travel, the world faces the greatest ever global pandemic of the century.", [["greatest", "OBSERVATION_MODIFIER", 94, 102], ["global", "OBSERVATION_MODIFIER", 108, 114], ["pandemic", "OBSERVATION", 115, 123]]], ["While uncertainty of an effective vaccine against SARS CoV2 persists, protective attributes of century old Bacillus Calmette-Gu\u00e9rin (BCG) vaccine is currently the hot topic of attention.IntroductionAt the beginning of the pandemic, it was predicted that the developing countries will face the maximum case fatalities because of poor health infrastructure, lack of preparedness, poor health regulations.", [["SARS", "DISEASE", 50, 54], ["Bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 107, 131], ["SARS CoV2", "ORGANISM", 50, 59], ["Bacillus Calmette-Gu\u00e9rin", "ORGANISM", 107, 131], ["BCG", "ORGANISM", 133, 136], ["Bacillus Calmette-Gu\u00e9rin", "SPECIES", 107, 131], ["an effective vaccine", "TREATMENT", 21, 41], ["SARS CoV2", "PROBLEM", 50, 59], ["century old Bacillus Calmette", "TREATMENT", 95, 124], ["Gu\u00e9rin (BCG) vaccine", "TREATMENT", 125, 145], ["poor health infrastructure", "PROBLEM", 328, 354]]], ["However, till now, the number of deaths have been higher in developed nations like USA and Europe.", [["deaths", "DISEASE", 33, 39], ["higher", "OBSERVATION_MODIFIER", 50, 56]]], ["Surprising, less number of cases are reported from Africa and majority of cases recovered with mild diseases.", [["mild diseases", "PROBLEM", 95, 108], ["less", "OBSERVATION_MODIFIER", 12, 16], ["mild", "OBSERVATION_MODIFIER", 95, 99], ["diseases", "OBSERVATION", 100, 108]]], ["Even if the number are increasing in India the severity and mortality are less in in compared to some countries.", [["increasing", "OBSERVATION_MODIFIER", 23, 33], ["less", "OBSERVATION_MODIFIER", 74, 78]]], ["In India, over 80% of the patients have mild symptoms or asymptomatic Hence, the inter-regional variation in the clinical severity and mortality of COVID-19 is speculated to be through immune response impact.", [["COVID-19", "CHEMICAL", 148, 156], ["COVID-19", "CHEMICAL", 148, 156], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["mild symptoms", "PROBLEM", 40, 53], ["asymptomatic", "PROBLEM", 57, 69], ["the inter-regional variation", "PROBLEM", 77, 105], ["the clinical severity", "PROBLEM", 109, 130], ["COVID", "TEST", 148, 153], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["symptoms", "OBSERVATION", 45, 53]]], ["It is also claimed that BCG vaccination offers partial protection and survival in low-income countries where tuberculosis is prevalent.1", [["tuberculosis", "DISEASE", 109, 121], ["BCG vaccination", "TREATMENT", 24, 39], ["partial protection", "TREATMENT", 47, 65], ["tuberculosis", "PROBLEM", 109, 121], ["tuberculosis", "OBSERVATION", 109, 121]]]], "PMC7433773": [["IntroductionIn December 2019, a novel pathogen emerged in China, spreading rapidly around the globe, to the point, where by March 2020, the World Health Organization (WHO) has declared the novel coronavirus (COVID-19) outbreak a global pandemic [1].", [["coronavirus", "DISEASE", 195, 206], ["COVID-19", "CHEMICAL", 208, 216], ["coronavirus", "ORGANISM", 195, 206], ["a novel pathogen", "PROBLEM", 30, 46], ["the novel coronavirus", "PROBLEM", 185, 206], ["globe", "ANATOMY", 94, 99]]], ["The clinical presentation of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranged between asymptomatic infection, mild symptoms and critical disease, defined by respiratory and/or multi-organ failure and death [2\u20135].IntroductionThe pandemic challenged healthcare systems worldwide, which confronted overwhelming burden of patients with COVID-19, emphasizing the critical role of effective patient\u2019s triage, to allow adequate clinical care for those deteriorating to critical COVID-19 [6\u20138].", [["respiratory", "ANATOMY", 189, 200], ["multi-organ", "ANATOMY", 208, 219], ["infection", "DISEASE", 29, 38], ["acute respiratory syndrome coronavirus", "DISEASE", 49, 87], ["infection", "DISEASE", 131, 140], ["respiratory and/or multi-organ failure", "DISEASE", 189, 227], ["death", "DISEASE", 232, 237], ["COVID-19", "CHEMICAL", 503, 511], ["multi-organ", "ORGAN", 208, 219], ["patients", "ORGANISM", 350, 358], ["patient", "ORGANISM", 417, 424], ["patients", "SPECIES", 350, 358], ["patient", "SPECIES", 417, 424], ["severe acute respiratory syndrome coronavirus", "SPECIES", 42, 87], ["SARS-CoV", "SPECIES", 91, 99], ["infection", "PROBLEM", 29, 38], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 42, 87], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["asymptomatic infection", "PROBLEM", 118, 140], ["mild symptoms", "PROBLEM", 142, 155], ["critical disease", "PROBLEM", 160, 176], ["multi-organ failure", "PROBLEM", 208, 227], ["death", "PROBLEM", 232, 237], ["COVID", "TEST", 364, 369], ["critical COVID", "TEST", 494, 508], ["infection", "OBSERVATION", 29, 38], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory syndrome", "OBSERVATION", 55, 75], ["infection", "OBSERVATION", 131, 140], ["mild", "OBSERVATION_MODIFIER", 142, 146], ["multi-organ", "ANATOMY", 208, 219], ["failure", "OBSERVATION", 220, 227]]], ["In the absence of effective triage, medical system insufficiency required national reinforcement actions in several instances [9], emphasizing the need for effective risk-prediction tools that are essential for viable healthcare system [10].IntroductionWhile identifying severe patients at their acute phase is clinically trivial, early identification of those at risk to deteriorate, and those with very low risk for critical disease, are the measures required for efficient triage.", [["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["medical system insufficiency", "PROBLEM", 36, 64], ["national reinforcement actions", "TREATMENT", 74, 104], ["critical disease", "PROBLEM", 418, 434], ["severe", "OBSERVATION_MODIFIER", 271, 277], ["trivial", "OBSERVATION", 322, 329], ["disease", "OBSERVATION", 427, 434]]], ["Only few baseline parameters were associated with poor COVID-19 outcome [11], including older age [12] and the presence of comorbidities [13, 14].", [["poor COVID", "PROBLEM", 50, 60], ["comorbidities", "PROBLEM", 123, 136]]], ["Other factors suggested had peak/nadir value at the severe disease phase, and not at baseline, and included hypoxia, thrombocytopenia [15], coagulation abnormalities (prolonged prothrombin time, high d-dimer levels [16, 17]), liver injury [18, 19], cellular (neutrophilia, lymphopenia) and cytokine-based immune-related parameters (increased interleukins six, eight and ten levels) [20] that led to assessment of interleukin-6 as a target for molecular inhibition [21], and high disease-severity scores [22].IntroductionMachine-learning (ML) algorithms enable assessment of the relations between input and output of complex processes.", [["liver", "ANATOMY", 226, 231], ["cellular", "ANATOMY", 249, 257], ["hypoxia", "DISEASE", 108, 115], ["thrombocytopenia", "DISEASE", 117, 133], ["coagulation abnormalities", "DISEASE", 140, 165], ["liver injury", "DISEASE", 226, 238], ["neutrophilia", "DISEASE", 259, 271], ["lymphopenia", "DISEASE", 273, 284], ["prothrombin", "GENE_OR_GENE_PRODUCT", 177, 188], ["d-dimer", "GENE_OR_GENE_PRODUCT", 200, 207], ["liver", "ORGAN", 226, 231], ["cellular", "CELL", 249, 257], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 413, 426], ["cytokine", "PROTEIN", 290, 298], ["interleukins", "PROTEIN", 342, 354], ["interleukin-6", "PROTEIN", 413, 426], ["peak/nadir value", "PROBLEM", 28, 44], ["the severe disease phase", "PROBLEM", 48, 72], ["hypoxia", "PROBLEM", 108, 115], ["thrombocytopenia", "PROBLEM", 117, 133], ["coagulation abnormalities", "PROBLEM", 140, 165], ["prolonged prothrombin time", "PROBLEM", 167, 193], ["high d-dimer levels", "TEST", 195, 214], ["liver injury", "PROBLEM", 226, 238], ["cellular (neutrophilia", "PROBLEM", 249, 271], ["lymphopenia", "PROBLEM", 273, 284], ["cytokine", "TEST", 290, 298], ["increased interleukins six", "PROBLEM", 332, 358], ["interleukin", "TEST", 413, 424], ["molecular inhibition", "TEST", 443, 463], ["high disease-severity scores", "PROBLEM", 474, 502], ["enable assessment", "TEST", 553, 570], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["disease", "OBSERVATION", 59, 66], ["thrombocytopenia", "OBSERVATION", 117, 133], ["liver", "ANATOMY", 226, 231], ["injury", "OBSERVATION", 232, 238], ["neutrophilia", "OBSERVATION", 259, 271], ["lymphopenia", "OBSERVATION", 273, 284], ["high disease", "OBSERVATION", 474, 486]]], ["In the context of risk stratification, ML models generate better performance than traditional prediction models [23, 24], owing to their ability to reveal nonlinear associations, superior optimization of multi-factorial algorithms and built-in methodologies for model validation [25, 26].", [["traditional prediction models", "TEST", 82, 111], ["multi-factorial algorithms", "PROBLEM", 204, 230], ["model validation", "TEST", 262, 278]]], ["The application of different ML models in feature selection and classification of multidimensional heterogeneous data, can provide promising tools for inference in medical practice [27] and was suggested for trend prediction [28] and risk stratification of patients with COVID-19 [29].IntroductionThe need for efficient triage facing the COVID-19 pandemic, forces us to seek in our toolbox for the optimal prediction tool in our possession.", [["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["different ML models", "TREATMENT", 19, 38], ["multidimensional heterogeneous data", "TEST", 82, 117], ["COVID", "TEST", 271, 276]]], ["Therefore, the aim of this study is to test the capabilities of ML models for the triage of patients with COVID-19, by predicting their risk for critical COVID-19 based on baseline clinical parameters.Population, patient selection, inclusion, and exclusion criteria ::: MethodsThis was a retrospective study, including all patients admitted to COVID-19 designated departments in a single tertiary medical center between March 8 and April 5, 2020.", [["patients", "ORGANISM", 92, 100], ["patient", "ORGANISM", 213, 220], ["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 92, 100], ["patient", "SPECIES", 213, 220], ["patients", "SPECIES", 323, 331], ["this study", "TEST", 22, 32], ["COVID", "TEST", 106, 111], ["critical COVID", "TEST", 145, 159], ["Methods", "TREATMENT", 270, 277], ["a retrospective study", "TEST", 286, 307]]], ["Patients included had confirmed COVID-19 infection based on reverse-transcriptase polymerase chain reaction (RT-PCR) for the SARS-CoV-2 ribonucleic acid (RNA).", [["infection", "DISEASE", 41, 50], ["ribonucleic acid", "CHEMICAL", 136, 152], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["reverse-transcriptase", "PROTEIN", 60, 81], ["SARS-CoV-2 ribonucleic acid", "RNA", 125, 152], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 125, 133], ["COVID", "TEST", 32, 37], ["19 infection", "PROBLEM", 38, 50], ["reverse-transcriptase polymerase chain reaction", "PROBLEM", 60, 107], ["RT-PCR", "TEST", 109, 115], ["the SARS", "TEST", 121, 129], ["CoV", "TEST", 130, 133], ["infection", "OBSERVATION", 41, 50]]], ["All patients were evaluated at the Sheba MC Department for Emergency Medicine, and underwent routine baseline evaluation, including recording of medical history, current complaints, measurement of vital signs, baseline testing for blood count, kidney and liver function tests, and inflammatory markers.Population, patient selection, inclusion, and exclusion criteria ::: MethodsSevere disease was defined by meeting one or more of the following criteria [30]: Respiratory rate \u2265 30 breaths/min, arterial oxygen saturation \u2264 93% at room air, and PaO2/FiO2 \u2264 300.", [["blood", "ANATOMY", 231, 236], ["kidney", "ANATOMY", 244, 250], ["liver", "ANATOMY", 255, 260], ["arterial", "ANATOMY", 495, 503], ["oxygen", "CHEMICAL", 504, 510], ["oxygen", "CHEMICAL", 504, 510], ["patients", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["kidney", "ORGAN", 244, 250], ["liver", "ORGAN", 255, 260], ["patient", "ORGANISM", 314, 321], ["arterial", "MULTI-TISSUE_STRUCTURE", 495, 503], ["oxygen", "SIMPLE_CHEMICAL", 504, 510], ["inflammatory markers", "PROTEIN", 281, 301], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 314, 321], ["routine baseline evaluation", "TEST", 93, 120], ["current complaints", "PROBLEM", 162, 180], ["vital signs", "TEST", 197, 208], ["baseline testing", "TEST", 210, 226], ["blood count", "TEST", 231, 242], ["kidney and liver function tests", "TEST", 244, 275], ["inflammatory markers", "TEST", 281, 301], ["MethodsSevere disease", "PROBLEM", 371, 392], ["Respiratory rate", "TEST", 460, 476], ["breaths/min", "TEST", 482, 493], ["arterial oxygen saturation", "TEST", 495, 521], ["PaO2", "TEST", 545, 549], ["FiO2", "TEST", 550, 554], ["kidney", "ANATOMY", 244, 250], ["liver", "ANATOMY", 255, 260], ["inflammatory", "OBSERVATION_MODIFIER", 281, 293], ["arterial", "ANATOMY", 495, 503]]], ["Critical patients were defined according to the following criteria: respiratory failure necessitating mechanical ventilation, hospitalization in ICU multi-organ failure and/or death [31].", [["respiratory", "ANATOMY", 68, 79], ["multi-organ", "ANATOMY", 149, 160], ["respiratory failure", "DISEASE", 68, 87], ["multi-organ failure", "DISEASE", 149, 168], ["death", "DISEASE", 176, 181], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["respiratory failure", "PROBLEM", 68, 87], ["mechanical ventilation", "TREATMENT", 102, 124], ["multi-organ failure", "PROBLEM", 149, 168], ["death", "PROBLEM", 176, 181], ["respiratory failure", "OBSERVATION", 68, 87], ["mechanical ventilation", "OBSERVATION", 102, 124], ["multi-organ", "ANATOMY", 149, 160], ["failure", "OBSERVATION", 161, 168]]], ["Patients with severe disease at presentation were excluded to allow unbiased analysis, for predicting deterioration in patients during their hospitalization.Artificial neural network ::: Machine learning models ::: MethodsArtificial neural network (ANN) was built using SPSS 25 interface, using hyperbolic tangent activation function for the hidden layer and Softmax activation function with cross-entropy error function for the output layer.", [["neural", "ANATOMY", 168, 174], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 119, 127], ["neural network", "MULTI-TISSUE_STRUCTURE", 168, 182], ["neural network", "MULTI-TISSUE_STRUCTURE", 233, 247], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 119, 127], ["severe disease", "PROBLEM", 14, 28], ["unbiased analysis", "TEST", 68, 85], ["hyperbolic tangent activation function", "TREATMENT", 295, 333], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["disease", "OBSERVATION", 21, 28]]], ["The network comprised an input layer including 16 normalized variables (14 covariate and two factors), one hidden layer and an output layer.", [["layer", "OBSERVATION_MODIFIER", 114, 119], ["output", "OBSERVATION_MODIFIER", 127, 133], ["layer", "OBSERVATION_MODIFIER", 134, 139]]], ["The network batch-trained over approximately 70% of the samples using scaled conjugate gradient as the optimization algorithm and tested on the remaining 30%.", [["samples", "ANATOMY", 56, 63], ["the samples", "TEST", 52, 63], ["scaled conjugate gradient", "TREATMENT", 70, 95], ["the optimization algorithm", "TEST", 99, 125]]], ["The model was validated using tenfold cross-validation method (training/test sample ratio: 70/30% \u00d7 10).", [["tenfold cross-validation method", "TREATMENT", 30, 61], ["training/test sample ratio", "TEST", 63, 89]]], ["In other words, 70% of all cases were randomly assigned to the training phase, and the remaining 30% to the test phase, the diagnostic ability was measured, and this procedure recurred for ten times.Random forest classification ::: Machine learning models ::: MethodsRandom forest classification (RF) model was built using Java-based statistical processor (JASP) platform [34], and was composed of an ensemble 42 randomized decision trees.", [["this procedure", "TREATMENT", 161, 175], ["MethodsRandom forest classification (RF) model", "TREATMENT", 260, 306]]], ["RF uses two powerful tools: The first is bagging, in which each decision tree in the forest is trained on a bootstrap sample of the training data (50% bootstrap samples in our analysis).", [["RF", "PROTEIN", 0, 2], ["the training data", "TEST", 128, 145], ["bootstrap samples", "TEST", 151, 168], ["our analysis", "TEST", 172, 184], ["bagging", "OBSERVATION", 41, 48]]], ["The second tool is random feature selection, in which RF randomly selects subset of features for decision rules at each node (20% holdout test data in the current analysis).", [["node", "ANATOMY", 120, 124], ["node", "MULTI-TISSUE_STRUCTURE", 120, 124], ["holdout test data", "TEST", 130, 147], ["the current analysis", "TEST", 151, 171]]], ["The cases not used for training [out-of-bag (OOB) samples] were used for cross-validation and optimization, with mean probability score per tree used for computing the model predictive ability.Classification and regression tree ::: Machine learning models ::: MethodsClassification and regression (CRT) decision tree model was built on SPSS 25 interface, using the CRT iterative classification method for automatic feature selection and predicting the target variable by splitting rules to classify the population into homogenous classes.", [["training", "TEST", 23, 31], ["cross-validation", "TEST", 73, 89], ["optimization", "TEST", 94, 106], ["MethodsClassification", "TEST", 260, 281], ["regression (CRT", "TREATMENT", 286, 301], ["automatic feature selection", "TEST", 405, 432]]], ["The model used Gini impurity measure to test the gain of each split and automatically selection of continuous variable optimal cutoffs.", [["Gini impurity measure", "TEST", 15, 36], ["optimal cutoffs", "OBSERVATION", 119, 134]]], ["Tenfold cross-validation was used for model testing and validation.Statistical analysis ::: MethodsData analysis was performed using SPSS version 25 (Armonk, NY) software [35] with two-sided significance level of \u03b1 = 0.05.", [["Tenfold cross-validation", "TEST", 0, 24], ["model testing", "TEST", 38, 51], ["validation", "TEST", 56, 66], ["Statistical analysis", "TEST", 67, 87], ["MethodsData analysis", "TEST", 92, 112], ["SPSS version", "TEST", 133, 145]]], ["Descriptive statistics are presented using prevalence and percentage values for categorical variables, while continuous variables are presented with means and standard deviation, skewed distributed variables are presented by median and range.", [["percentage values", "TEST", 58, 75], ["categorical variables", "TEST", 80, 101], ["skewed distributed variables", "PROBLEM", 179, 207]]], ["Group comparisons were tested using Student\u2019s t test for continuous normally distributed variables, and the Mann\u2013Whitney U test for non-parametric comparisons.", [["Student\u2019s t test", "TEST", 36, 52], ["the Mann\u2013Whitney U test", "TEST", 104, 127], ["non-parametric comparisons", "TEST", 132, 158]]], ["Categorical comparisons were tested using the \u03c72 test or the Fisher\u2019s exact test, as appropriate.Statistical analysis ::: MethodsROC analysis was used to evaluate the associations of different variables with critical COVID-19 infections by calculating the ROC AUC.", [["infections", "DISEASE", 226, 236], ["the \u03c72 test", "TEST", 42, 53], ["MethodsROC analysis", "TEST", 122, 141], ["critical COVID-19 infections", "PROBLEM", 208, 236], ["the ROC AUC", "TEST", 252, 263]]], ["Cutoffs for optimal prediction were selected using Youden index and variables performance parameters were computed, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy.", [["Cutoffs", "TEST", 0, 7], ["Youden index", "TEST", 51, 63], ["variables performance parameters", "TEST", 68, 100], ["sensitivity", "TEST", 126, 137], ["PPV", "TEST", 179, 182], ["NPV", "TEST", 212, 215], ["accuracy", "TEST", 221, 229]]], ["Comparison of the prediction ability was performed based on the above measures and the balance accuracy measures, such as F1 score", [["the prediction ability", "TEST", 14, 36], ["the above measures", "TREATMENT", 60, 78], ["the balance accuracy measures", "TEST", 83, 112]]]], "PMC7461847": [["IntroductionCorona virus infectious disease 19 (COVID-19) is a seriously alarming pandemic (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).", [["IntroductionCorona virus infectious disease", "DISEASE", 0, 43], ["IntroductionCorona virus", "ORGANISM", 0, 24], ["IntroductionCorona virus infectious disease 19 (COVID-19", "SPECIES", 0, 56], ["IntroductionCorona virus infectious disease", "PROBLEM", 0, 43], ["COVID", "TEST", 48, 53], ["a seriously alarming pandemic", "PROBLEM", 61, 90]]], ["As of 13th June 2020, about 7,495,164 confirmed cases and 421,976 confirmed deaths have been reported globally by the World health Organization (WHO) (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).", [["deaths", "DISEASE", 76, 82]]], ["An interesting study in The Lancet Global Health journal, by Qian Liu and colleagues, highlighted the experiences of HCPs during the COVID-19 crisis in China, which by the way also provides a picture of the challenges faced by the HCPs all over the world during the COVID-19 outbreak.", [["An interesting study", "TEST", 0, 20], ["the COVID", "TEST", 129, 138], ["the COVID", "TEST", 262, 271]]], ["In that study, the authors emphasized that the high risk of infection and insufficient personal protective equipment are among the main causes of enormous pressure on HCPs during the outbreak (Liu et al., 2020).", [["infection", "DISEASE", 60, 69], ["that study", "TEST", 3, 13], ["infection", "PROBLEM", 60, 69], ["insufficient personal protective equipment", "TREATMENT", 74, 116], ["infection", "OBSERVATION", 60, 69], ["enormous", "OBSERVATION_MODIFIER", 146, 154], ["pressure", "OBSERVATION_MODIFIER", 155, 163]]], ["Undoubtedly, safety of HCPs is of crucial importance, and ensuring their safety will ensure efficacy in crisis management and COVID-19 containment.IntroductionThe severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus which causes COVID-19 (Gorbalenya et al., 2020).", [["acute respiratory syndrome", "DISEASE", 170, 196], ["severe acute respiratory syndrome corona virus 2", "ORGANISM", 163, 211], ["SARS-CoV-2", "ORGANISM", 213, 223], ["severe acute respiratory syndrome corona virus", "SPECIES", 163, 209], ["SARS-CoV-2", "SPECIES", 213, 223], ["crisis management", "TREATMENT", 104, 121], ["COVID", "TREATMENT", 126, 131], ["The severe acute respiratory syndrome corona virus", "PROBLEM", 159, 209], ["SARS-CoV", "TEST", 213, 221], ["an enveloped positive", "PROBLEM", 228, 249], ["stranded RNA virus", "PROBLEM", 250, 268], ["COVID", "TEST", 282, 287], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory syndrome", "OBSERVATION", 176, 196], ["stranded RNA virus", "OBSERVATION", 250, 268]]], ["In fact, breathing and talking of an infected person, produce numerous aerosol particles which pose a threat of infection if they are inhaled by nearby close persons (Meselson, 2020).", [["infection", "DISEASE", 112, 121], ["person", "SPECIES", 46, 52], ["persons", "SPECIES", 158, 165], ["numerous aerosol particles", "TREATMENT", 62, 88], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 112, 121]]], ["Moreover, a contact hazard usually develops since these particles might settle on surfaces, and remain viable/infective for several hours (van Doremalen et al., 2020).", [["a contact hazard", "PROBLEM", 10, 26], ["infective", "PROBLEM", 110, 119], ["infective", "OBSERVATION", 110, 119]]], ["In other cases, these particles could be too small to settle and remain dispersed by air turbulence, posing an inhalation threat even at considerable distances (Meselson, 2020).", [["air turbulence", "OBSERVATION", 85, 99]]], ["Consequently, these observations highlight the crucial importance of providing adequate personal protective equipment and clothes especially for the HCPs while taking care of COVID-19 patients.IntroductionCareful consideration for the structural features of SARS-CoV-2 will provide insights for better therapeutic as well as protective measures to combat COVID-19.", [["SARS", "DISEASE", 258, 262], ["COVID-19", "CHEMICAL", 355, 363], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["SARS", "PROBLEM", 258, 262], ["CoV", "TEST", 263, 266], ["protective measures", "TREATMENT", 325, 344], ["COVID", "TEST", 355, 360]]], ["Basically, the SARS-CoV-2 has four major structural proteins: the spike (S) protein, the envelope (E) protein, membrane (M) protein, and the nucleocapsid (N) protein (Schoeman and Fielding, 2019; Kang et al., 2020; Ou et al., 2020).", [["membrane", "ANATOMY", 111, 119], ["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 89, 101], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["SARS-CoV-2", "DNA", 15, 25], ["structural proteins", "PROTEIN", 41, 60], ["spike (S) protein", "PROTEIN", 66, 83], ["envelope (E) protein", "PROTEIN", 89, 109], ["membrane (M) protein", "PROTEIN", 111, 131], ["nucleocapsid (N) protein", "PROTEIN", 141, 165], ["SARS-CoV", "SPECIES", 15, 23], ["the SARS", "TEST", 11, 19], ["protein", "TEST", 76, 83], ["the envelope (E) protein", "TEST", 85, 109], ["protein", "TEST", 124, 131], ["the nucleocapsid", "TEST", 137, 153]]], ["Like other RNA viruses, SARS-CoV-2 consists of a negatively charged RNA enveloped inside a positively charged capsid that holds this genetic material firmly and plays a very important role in the virus infectivity (Belyi and Muthukumar, 2006; Hu et al., 2008; Forrey and Muthukumar, 2009).IntroductionKnowing that the particle size of the virus was reported to be in the range of 70\u201390 nm (Kim et al., 2020).", [["SARS", "DISEASE", 24, 28], ["SARS-CoV-2", "ORGANISM", 24, 34], ["SARS-CoV", "SPECIES", 24, 32], ["other RNA viruses", "PROBLEM", 5, 22], ["SARS", "PROBLEM", 24, 28], ["a negatively charged RNA", "PROBLEM", 47, 71], ["the virus", "PROBLEM", 335, 344], ["RNA viruses", "OBSERVATION", 11, 22], ["particle", "OBSERVATION_MODIFIER", 318, 326], ["size", "OBSERVATION_MODIFIER", 327, 331]]], ["Therefore, SARS-CoV-2 is considered a colloidal particle and a nanoparticle, specifically, and hence likewise all the colloidal particles, it carries a zeta-potential which in this case as previously mentioned is mostly assumed to be a positive one, primarily due to its capsid (Forrey and Muthukumar, 2009).IntroductionLuckily, the previous knowledge about corona-viruses helped the scientific community to achieve rapid progress in understanding SARS-CoV-2, however much remains unknown, and its biology is still far from complete elucidation and new discoveries and findings are emerging every day (Andersen et al., 2020; Gorbalenya et al., 2020).", [["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 448, 452], ["SARS-CoV-2", "ORGANISM", 448, 458], ["SARS-CoV", "SPECIES", 448, 456], ["a colloidal particle", "TREATMENT", 36, 56], ["colloidal particle", "OBSERVATION", 38, 56], ["colloidal particles", "OBSERVATION", 118, 137], ["zeta-potential", "OBSERVATION_MODIFIER", 152, 166], ["positive", "OBSERVATION", 236, 244]]], ["For example, it's noteworthy in this context to mention that novel polybasic (arginine rich) motifs, imparting a positive zeta potential at the physiological pH, have been identified in the spike protein of SARS-CoV-2, which seems to be a distinguishing unique feature compared to several previous SARS-related sequences (Jaimes et al., 2020).", [["arginine", "CHEMICAL", 78, 86], ["SARS", "DISEASE", 298, 302], ["arginine", "CHEMICAL", 78, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 207, 217], ["polybasic (arginine rich) motifs", "PROTEIN", 67, 99], ["spike protein", "PROTEIN", 190, 203], ["SARS-related sequences", "DNA", 298, 320], ["SARS-CoV", "SPECIES", 207, 215], ["novel polybasic (arginine rich)", "TREATMENT", 61, 92], ["a positive zeta potential", "PROBLEM", 111, 136], ["SARS", "PROBLEM", 207, 211], ["CoV", "TEST", 212, 215], ["positive zeta", "OBSERVATION_MODIFIER", 113, 126]]], ["These motifs were reported to play important role during the process of SARS-CoV-2 entrance to host cells together with implications on virus infectivity (Hoffmann et al., 2020; Jaimes et al., 2020).IntroductionIn this context, we introduce an opinion that could serve health-care providers by exploiting positively charged polymers such as chitosan in order to prepare nanofibers possessing a positive zeta-potential which can be incorporated in the personal protective clothes (fabrics) of the health-care providers and could lead to the electrostatic virus repulsion and hence decrease the viral load around those health-care providers.IntroductionThe produced nanofibers are either directly electrospun into membranes or fabrics or can be integrated in protective clothes by physical adsorption and adhesion to the clothes material thanks to their very high surface area (Baji et al., 2020).Why Chitosan?Chitosan is a natural cationic polysaccharide that exhibits many remarkable properties such as biocompatibility, biodegradability, non-toxicity, hemostatic and bio-adhesiveness and penetration enhancing properties (Abdel-Hafez et al., 2014, 2018).", [["cells", "ANATOMY", 100, 105], ["membranes", "ANATOMY", 712, 721], ["surface area", "ANATOMY", 862, 874], ["chitosan", "CHEMICAL", 341, 349], ["Chitosan", "CHEMICAL", 899, 907], ["Chitosan", "CHEMICAL", 908, 916], ["host cells", "CELL", 95, 105], ["chitosan", "SIMPLE_CHEMICAL", 341, 349], ["membranes", "CELLULAR_COMPONENT", 712, 721], ["Chitosan", "SIMPLE_CHEMICAL", 899, 907], ["Chitosan", "SIMPLE_CHEMICAL", 908, 916], ["host cells", "CELL_TYPE", 95, 105], ["CoV-2 entrance to host cells", "TREATMENT", 77, 105], ["virus infectivity", "PROBLEM", 136, 153], ["positively charged polymers", "TREATMENT", 305, 332], ["chitosan", "TREATMENT", 341, 349], ["nanofibers", "TREATMENT", 370, 380], ["a positive zeta-potential", "PROBLEM", 392, 417], ["the electrostatic virus repulsion", "PROBLEM", 536, 569], ["The produced nanofibers", "TREATMENT", 651, 674], ["fabrics", "TREATMENT", 725, 732], ["Chitosan", "TREATMENT", 908, 916], ["a natural cationic polysaccharide", "TREATMENT", 920, 953], ["non-toxicity", "PROBLEM", 1039, 1051], ["hemostatic and bio-adhesiveness and penetration enhancing properties", "PROBLEM", 1053, 1121], ["positive zeta-potential", "OBSERVATION_MODIFIER", 394, 417]]], ["Moreover, chitosan has remarkable anti-microbial properties in addition to being abundant and in-expensive (Qi et al., 2004; Abdel-Hafez et al., 2018).", [["chitosan", "CHEMICAL", 10, 18], ["chitosan", "SIMPLE_CHEMICAL", 10, 18], ["chitosan", "TREATMENT", 10, 18], ["anti-microbial properties", "OBSERVATION_MODIFIER", 34, 59]]], ["It is worth noting, that quaternized chitosan such as the oldest form N,N,N-trimethyl chitosan (TMC) or the most recently prepared derivatives; the single N-quaternized (QCS) and the double N-diquaternized (DQCS) chitosan derivatives, possessing more positively charged amino groups can give better viral repulsion results.", [["chitosan", "CHEMICAL", 37, 45], ["N,N,N-trimethyl chitosan", "CHEMICAL", 70, 94], ["TMC", "CHEMICAL", 96, 99], ["QCS", "CHEMICAL", 170, 173], ["DQCS", "CHEMICAL", 207, 211], ["chitosan", "CHEMICAL", 213, 221], ["N,N,N-trimethyl chitosan", "CHEMICAL", 70, 94], ["TMC", "CHEMICAL", 96, 99], ["N", "CHEMICAL", 155, 156], ["N", "CHEMICAL", 190, 191], ["amino", "CHEMICAL", 270, 275], ["chitosan", "SIMPLE_CHEMICAL", 37, 45], ["N,N-trimethyl chitosan", "SIMPLE_CHEMICAL", 72, 94], ["TMC", "SIMPLE_CHEMICAL", 96, 99], ["QCS", "SIMPLE_CHEMICAL", 170, 173], ["double N-diquaternized (DQCS) chitosan derivatives", "SIMPLE_CHEMICAL", 183, 233], ["quaternized chitosan", "TREATMENT", 25, 45], ["N-trimethyl chitosan (TMC)", "TREATMENT", 74, 100], ["the single N-quaternized (QCS)", "TREATMENT", 144, 174], ["the double N-diquaternized (DQCS) chitosan derivatives", "TREATMENT", 179, 233]]], ["However, for large-scale production purposes, we propose to use chitosan due to its wide-abundance and availability rather than its derivatives that warrant long chemical synthesis schemes for their production (Farid et al., 2014; El-Marakby et al., 2017; Luan et al., 2018; Abdelhamid et al., 2019).Why Electrospinning?The electrospinning technique provides non-wovens to the order of few nanometers with large surface areas, ease of functionalization for various purposes and superior mechanical properties.", [["surface", "ANATOMY", 412, 419], ["chitosan", "CHEMICAL", 64, 72], ["chitosan", "SIMPLE_CHEMICAL", 64, 72], ["large-scale production purposes", "TREATMENT", 13, 44], ["chitosan", "TREATMENT", 64, 72], ["its derivatives", "TREATMENT", 128, 143], ["long chemical synthesis schemes", "TREATMENT", 157, 188], ["The electrospinning technique", "TREATMENT", 320, 349], ["large surface areas", "TREATMENT", 406, 425], ["functionalization", "TREATMENT", 435, 452], ["various purposes", "TREATMENT", 457, 473], ["superior mechanical properties", "TREATMENT", 478, 508], ["large", "OBSERVATION_MODIFIER", 406, 411], ["surface", "OBSERVATION_MODIFIER", 412, 419], ["superior", "OBSERVATION_MODIFIER", 478, 486], ["mechanical properties", "OBSERVATION", 487, 508]]], ["Also, the possibility of large scale productions combined with the simplicity of the process makes this technique very attractive for many different applications.", [["large scale productions", "PROBLEM", 25, 48], ["this technique", "TREATMENT", 99, 113], ["large", "OBSERVATION_MODIFIER", 25, 30], ["scale", "OBSERVATION_MODIFIER", 31, 36], ["productions", "OBSERVATION", 37, 48]]], ["The biomedical field is one of the important application areas among others utilizing the technique of electrospinning whether for drug delivery or for protection or prophlaxis purposes (Agarwal et al., 2008).Why Nanofibers?Electrospinning has several merits of simplicity, high efficiency, low cost, and high reproducibility.", [["the technique of electrospinning", "TREATMENT", 86, 118], ["drug delivery", "TREATMENT", 131, 144], ["protection", "TREATMENT", 152, 162], ["Electrospinning", "TREATMENT", 224, 239], ["high efficiency", "PROBLEM", 274, 289], ["low cost", "PROBLEM", 291, 299], ["high efficiency", "OBSERVATION_MODIFIER", 274, 289], ["low cost", "OBSERVATION_MODIFIER", 291, 299], ["high reproducibility", "OBSERVATION", 305, 325]]], ["Electrospinning was first invented as a patent to produce continuous fibers in 1934.", [["Electrospinning", "TREATMENT", 0, 15], ["patent", "OBSERVATION", 40, 46]]], ["Since this date, high attention was given to this valuable technique and its applications.", [["this valuable technique", "TREATMENT", 45, 68]]], ["Compared to conventional fibrous structures, nanofibers are lightweight with small diameters in the nano range, controllable pore structures and high surface-to-volume ratio.", [["fibrous structures", "ANATOMY", 25, 43], ["pore structures", "ANATOMY", 125, 140], ["surface", "ANATOMY", 150, 157], ["fibrous structures", "TISSUE", 25, 43], ["lightweight", "OBSERVATION_MODIFIER", 60, 71], ["small", "OBSERVATION_MODIFIER", 77, 82], ["diameters", "OBSERVATION_MODIFIER", 83, 92], ["nano range", "OBSERVATION", 100, 110], ["controllable", "OBSERVATION_MODIFIER", 112, 124], ["pore", "OBSERVATION_MODIFIER", 125, 129], ["high", "OBSERVATION_MODIFIER", 145, 149], ["surface", "OBSERVATION_MODIFIER", 150, 157]]], ["These remarkable properties make them ideal for use in a wide array of applications such as filtration, sensors, protective clothing, tissue engineering, functional materials, and energy storage (Cai et al., 2012).Proposed Method of the Chitosan Nanofibers Incorporation Into Textiles and FabricsA straight forward and a simple approach of incorporating electrospun fibers into textile involves electrospinning the fibers directly on the surface of the textile or fabric to obtain a composite fabric.", [["tissue", "ANATOMY", 134, 140], ["fibers", "ANATOMY", 366, 372], ["fibers", "ANATOMY", 415, 421], ["surface", "ANATOMY", 438, 445], ["Chitosan", "CHEMICAL", 237, 245], ["tissue", "TISSUE", 134, 140], ["Chitosan Nanofibers", "SIMPLE_CHEMICAL", 237, 256], ["fibers", "CELLULAR_COMPONENT", 415, 421], ["a wide array of applications", "TREATMENT", 55, 83], ["filtration", "TREATMENT", 92, 102], ["sensors", "TREATMENT", 104, 111], ["protective clothing", "TREATMENT", 113, 132], ["tissue engineering", "TREATMENT", 134, 152], ["the Chitosan Nanofibers Incorporation", "TREATMENT", 233, 270], ["a simple approach", "TREATMENT", 319, 336], ["incorporating electrospun fibers into textile", "TREATMENT", 340, 385], ["a composite fabric", "TREATMENT", 481, 499], ["textile", "ANATOMY", 453, 460], ["composite fabric", "OBSERVATION", 483, 499]]], ["This approach of depositing fibers on the surface of the fabric is considered highly economic and reduces the number of manufacturing steps and therefore is appropriate for mass production (Vitchuli et al., 2010).", [["fibers", "ANATOMY", 28, 34], ["surface", "ANATOMY", 42, 49], ["fibers", "CELLULAR_COMPONENT", 28, 34], ["surface", "CELLULAR_COMPONENT", 42, 49], ["mass production", "PROBLEM", 173, 188], ["depositing", "OBSERVATION_MODIFIER", 17, 27], ["fibers", "OBSERVATION", 28, 34], ["surface", "OBSERVATION_MODIFIER", 42, 49], ["fabric", "OBSERVATION", 57, 63], ["highly", "OBSERVATION_MODIFIER", 78, 84], ["economic", "OBSERVATION", 85, 93], ["number", "OBSERVATION_MODIFIER", 110, 116], ["manufacturing steps", "OBSERVATION", 120, 139]]], ["Increasing the bonding efficiency of the deposited nanofibers and the fabrics or textiles can be achieved through several techniques whether thermal, through the deposition of several dense layers, needling and hydro-entanglement or through the use of an adhesive (Midha and Dakuri, 2017).", [["the deposited nanofibers", "TREATMENT", 37, 61], ["several dense layers, needling and hydro-entanglement", "PROBLEM", 176, 229], ["bonding efficiency", "OBSERVATION", 15, 33], ["several", "OBSERVATION_MODIFIER", 176, 183], ["dense", "OBSERVATION_MODIFIER", 184, 189], ["layers", "OBSERVATION_MODIFIER", 190, 196], ["needling", "OBSERVATION", 198, 206], ["adhesive", "OBSERVATION_MODIFIER", 255, 263]]], ["Furthermore, the electrospun chitosan nanofibers were successfully mass produced and its large-scale production was previously reported through a Force spinning technology\u00ae (Zhang et al., 2008; Xu et al., 2014).Proposed Method of the Chitosan Nanofibers Incorporation Into Textiles and FabricsFigure 1 presents a schematic summary of the proposed idea.Author ContributionsRH: conceptualization, hypothesis, methodology, discussion, writing, and revision.", [["chitosan", "CHEMICAL", 29, 37], ["Chitosan", "CHEMICAL", 234, 242], ["electrospun chitosan nanofibers", "SIMPLE_CHEMICAL", 17, 48], ["the electrospun chitosan nanofibers", "TREATMENT", 13, 48], ["successfully mass", "PROBLEM", 54, 71], ["the Chitosan Nanofibers Incorporation", "TREATMENT", 230, 267], ["revision", "TREATMENT", 445, 453], ["mass", "OBSERVATION", 67, 71], ["large", "OBSERVATION_MODIFIER", 89, 94]]], ["DK: methodology, discussion, writing, and revision.", [["revision", "TREATMENT", 42, 50]]]], "PMC7150068": [["The 1996 declaration of World Food Summit at Rome had reaffirmed the right of everyone to have access to safe and nutritious food, consistent with the right to adequate food, and fundamental right of everyone to be free from hunger (FAO, 1996).IntroductionAfter independence in 1947, India created the basic document for effective governance in 1950, that is, Constitution of India, which provided every Indian citizen a fundamental \u201cright to food.\u201d", [["right", "ANATOMY_MODIFIER", 69, 74], ["right", "ANATOMY_MODIFIER", 151, 156], ["right", "ANATOMY_MODIFIER", 191, 196]]], ["\u201cFood Security Act\u201d was implemented in September 2013, which entitled almost two-third of 1.2 billion Indian citizens, the right to sufficient, nutritious and quality food at affordable price (highly subsidized through public distribution system).", [["right", "ANATOMY_MODIFIER", 123, 128]]], ["Food Safety and Standards Authority of India (FSSAI) has recently started working on how to implement Food Law in India.IntroductionWHO gives high priority to food safety, quality and consumer protection programs and food safety is an essential public health function.", [["consumer protection programs", "TREATMENT", 184, 212]]], ["Food-borne diseases (FBD) result in substantial burden on healthcare systems, trade and tourism, market access; and reduce economic productivity and threaten livelihood.", [["Food-borne diseases", "DISEASE", 0, 19], ["FBD", "DISEASE", 21, 24], ["borne diseases", "PROBLEM", 5, 19], ["substantial burden on healthcare systems", "PROBLEM", 36, 76], ["substantial", "OBSERVATION_MODIFIER", 36, 47], ["burden", "OBSERVATION_MODIFIER", 48, 54]]], ["But FBDs generally go undetected, mostly due to lack of communication among the human, veterinary, agriculture, and food sectors.IntroductionAs per WHO (2015) global human movements are increasing as also the international food trade, resulting in new risks to food safety since more and more people want to eat out to try new varieties of foods.", [["human movements", "DISEASE", 166, 181], ["human", "ORGANISM", 80, 85], ["human", "ORGANISM", 166, 171], ["people", "ORGANISM", 293, 299], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 166, 171], ["people", "SPECIES", 293, 299], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 166, 171]]], ["Such new trends are also modifying the patterns of food production, distribution and consumption, integrating agricultural and food industries.", [["new", "OBSERVATION_MODIFIER", 5, 8], ["food industries", "OBSERVATION", 127, 142]]], ["The global value of food trade now exceeds US$500 billion.", [["global", "OBSERVATION_MODIFIER", 4, 10]]], ["However, globalization of food trade has also brought new challenges and risks to food control and regulations and even a single source of contamination may become widespread, with global consequences.", [["contamination", "PROBLEM", 139, 152], ["food trade", "OBSERVATION", 26, 36]]], ["Antimicrobial resistance to food-borne pathogens; emergence of new pathogens, chemical contaminants, new technologies in food production and processing, like genetic engineering and nanotechnology, changing animal food production and animal husbandry practices, are impacting consumer safety (FAO/WHO-Provisional Edition, 2005).IntroductionOn the World Health Day (Apr. 7, 2015), WHO gave a slogan \u201cFrom farm to plate, make food safe.\u201d", [["Antimicrobial resistance", "PROBLEM", 0, 24], ["borne pathogens", "PROBLEM", 33, 48], ["new pathogens", "PROBLEM", 63, 76], ["chemical contaminants", "PROBLEM", 78, 99]]], ["According to Director of WHO\u2019s Department of Food Safety and Zoonoses, it often takes a crisis for the collective consciousness on food safety to be stirred and any serious response to be taken.", [["a crisis", "PROBLEM", 86, 94]]], ["Almost one third (30%) of all deaths from FBDs, caused by 31 agents\u2014bacteria, viruses, parasites, toxins, and chemicals, are in children under 5 years, despite the fact that they make up only 9% of the global population.", [["deaths", "DISEASE", 30, 36], ["FBDs", "DISEASE", 42, 46], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["all deaths from FBDs", "PROBLEM", 26, 46], ["bacteria", "PROBLEM", 68, 76], ["viruses", "PROBLEM", 78, 85], ["parasites", "PROBLEM", 87, 96]]], ["The report, states that each year as many as 600 million, or almost 1 in 10 people in the world, fall ill after consuming contaminated food.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82]]], ["Of these, 420,000 people die, including 125,000 children under the age of 5 years.", [["people", "ORGANISM", 18, 24], ["children", "ORGANISM", 48, 56], ["people", "SPECIES", 18, 24], ["children", "SPECIES", 48, 56]]], ["Until now, such estimates of FBDs were vague and imprecise (WHO, 2015).", [["vague", "PROBLEM", 39, 44]]], ["As mentioned by Director-General of WHO \u201cKnowing which food-borne pathogens are causing biggest problems in which parts of world can generate targeted public health action by the governments, food industry, and public.\u201dIntroductionWHO had established Global Food-borne Infections Network (GFN) to strengthen national and regional integrated surveillance, investigation, prevention, and control of food-borne and other enteric infections.", [["Food-borne Infections", "DISEASE", 258, 279], ["enteric infections", "DISEASE", 418, 436], ["regional integrated surveillance", "TEST", 321, 353], ["investigation", "TEST", 355, 368], ["prevention", "TREATMENT", 370, 380], ["other enteric infections", "PROBLEM", 412, 436], ["enteric", "ANATOMY", 418, 425], ["infections", "OBSERVATION", 426, 436]]], ["The network promotes integrated, laboratory-based surveillance and fosters intersectoral collaboration and communication among microbiologists and epidemiologists in human health, veterinary and food-related disciplines (WHO, 2013).", [["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171]]], ["Early warning system, based on robust risk assessment to inform action, is very useful in addressing health threats and their timely communication.", [["robust risk assessment", "TEST", 31, 53]]], ["In response to threats such as the avian influenza virus H5N1 and severe acute respiratory syndrome (SARS), the Global Early Warning System (GLEWS) for Transboundary Animal Diseases, including Zoonoses, was jointly established by WHO, FAO, and OIE.", [["influenza virus H5N1", "DISEASE", 41, 61], ["acute respiratory syndrome", "DISEASE", 73, 99], ["SARS", "DISEASE", 101, 105], ["avian", "ORGANISM", 35, 40], ["influenza virus H5N1", "ORGANISM", 41, 61], ["avian influenza virus H5N1", "SPECIES", 35, 61], ["the avian influenza virus H5N1", "PROBLEM", 31, 61], ["severe acute respiratory syndrome", "PROBLEM", 66, 99], ["Transboundary Animal Diseases", "PROBLEM", 152, 181], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory syndrome", "OBSERVATION", 79, 99], ["Diseases", "OBSERVATION", 173, 181]]], ["GLEWS builds on existing internal systems of three participating organizations to confidentially track and verify events in order to improve harmonization and decrease duplication.", [["decrease duplication", "PROBLEM", 159, 179], ["decrease duplication", "OBSERVATION", 159, 179]]], ["It embodies a unique cross-sectoral and multidisciplinary partnership for early identification and assessment of health risks at the human\u2013animal\u2013ecosystem interface.", [["early identification", "TEST", 74, 94], ["assessment", "TEST", 99, 109]]], ["To insure a comprehensive approach, GLEWS links with INFOSAN to insure and promote seamless action throughout food value chain within human\u2013animal\u2013ecosystem interface (WHO, 2013).IntroductionEnforcing food safety standards requires a food chain that is highly controlled and supplied with appropriate data on contaminants, hazards, and risk management strategies.", [["INFOSAN", "TREATMENT", 53, 60], ["a food chain", "TREATMENT", 232, 244], ["risk management strategies", "TREATMENT", 336, 362]]], ["Experts at FAO and WHO have observed that when incidence of FBD and number of disruptions to international trade in foodstuffs are increasing, it has never been more important for countries to implement an effective food safety system, guided by modern concept of risk analysis, to respond to current challenges (FAO/WHO-Provisional Edition, 2005), namely:1.Traditional food safety systems are inadequate to cope with complex, persistent, pervasive, and evolving array of food safety issues existing today.2.Modern food safety systems need to be science based to effectively cope with, and respond to wide range of food safety challenges presently confronting countries.3.Science-based approaches are an essential part of risk analysis framework and crucial to creating a modern and effective food safety system.", [["FBD", "DISEASE", 60, 63], ["FBD", "PROBLEM", 60, 63], ["Modern food safety systems", "TREATMENT", 508, 534]]]], "PMC7228356": [["The COVID\u201019 patient is the main source of infection, and asymptomatic infective patient can also be a source of infection (Bhadelia 2020).", [["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 113, 122], ["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 81, 88], ["infection", "PROBLEM", 43, 52], ["asymptomatic infective", "PROBLEM", 58, 80], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 43, 52], ["asymptomatic", "OBSERVATION_MODIFIER", 58, 70], ["infective", "OBSERVATION", 71, 80], ["infection", "OBSERVATION", 113, 122]]], ["The main route of transmission is through respiratory droplets and contact (Burki 2020).", [["respiratory droplets", "ANATOMY", 42, 62], ["main", "OBSERVATION_MODIFIER", 4, 8], ["respiratory droplets", "OBSERVATION", 42, 62]]]]}